De ontwikkeling van krachtige en selectieve inhibitoren van hepatitis A en E virus by Debing, Yannick
  
 
1 
 
 
KU Leuven 
Biomedical Sciences Group 
Faculty of Medicine 
Department of Microbiology and Immunology 
 
 
 
 
 
 
 
TOWARDS THE DEVELOPMENT 
OF POTENT AND SELECTIVE 
INHIBITORS OF HEPATITIS A 
AND E VIRUS 
 
April 2015 
Dissertation presented in 
partial fulfilment of the 
requirements for the 
degree of Doctor in 
Pharmaceutical Sciences 
Jury: 
 
Promoter:  Prof. Dr. Johan Neyts 
Chair:   Prof. Dr. Arthur Van Aerschot 
Secretary:  Prof. Dr. David Cassiman 
Jury members: Prof. Dr. David Cassiman 
  Prof. Dr. Dominique Schols 
  Prof. Dr. Etienne Sokal 
  Dr. Annelies Riezebos-Brilman 
Yannick DEBING 
2 
 
  
3 
 
Table of contents 
 
Dankwoord – Acknowledgements ................................................................................................. 7 
List of abbreviations ..................................................................................................................... 9 
Summary ................................................................................................................................... 13 
Samenvatting ............................................................................................................................. 15 
Chapter 1: General introduction to hepatitis A virus and hepatitis E virus .................................... 17 
1.1 Hepatitis A virus.................................................................................................................... 18 
1.1.1 HAV genome organization and replication cycle .......................................................... 18 
1.1.2 Cell culture .................................................................................................................... 23 
1.1.3 The need for antivirals? ................................................................................................ 24 
1.2 Hepatitis E virus .................................................................................................................... 24 
1.2.1 HEV molecular virology ................................................................................................. 24 
1.2.2 Hepatitis E..................................................................................................................... 27 
1.2.3 Current control strategies ............................................................................................. 29 
1.2.4 Why do we need antiviral drugs against hepatitis E virus? ........................................... 29 
1.3 Thesis objectives................................................................................................................... 31 
Chapter 2: Rapid and convenient assays to assess potential inhibitory activity on in vitro hepatitis A 
virus replication ......................................................................................................................... 33 
2.1 Introduction .......................................................................................................................... 34 
2.2 Materials and methods......................................................................................................... 35 
2.2.1 Cells and viruses ........................................................................................................... 35 
2.2.2 Compounds................................................................................................................... 36 
2.2.3 CPE reduction assay ...................................................................................................... 36 
2.2.4 HM175/18 f virus yield assay ........................................................................................ 37 
2.2.5 PA21 virus yield assay ................................................................................................... 37 
2.2.6 HAV8Y-Bsd virus yield assay ......................................................................................... 37 
2.2.7 RT-qPCR ........................................................................................................................ 37 
2.3 Results .................................................................................................................................. 38 
2.4 Discussion ............................................................................................................................. 42 
Chapter 3: Cutthroat trout virus as a surrogate in vitro infection model for testing inhibitors of 
hepatitis E virus replication......................................................................................................... 47 
3.1 Results and discussion .......................................................................................................... 48 
4 
 
Chapter 4: Ribavirin inhibits in vitro hepatitis E virus replication through depletion of cellular GTP 
pools and is moderately synergistic with interferon alpha ........................................................... 55 
4.1 Introduction .......................................................................................................................... 56 
4.2 Materials and methods......................................................................................................... 57 
4.2.1 In vitro transcription and capping ................................................................................. 57 
4.2.2 Cells and viruses ........................................................................................................... 57 
4.2.3 Compounds................................................................................................................... 58 
4.2.4 Luminescence-based antiviral assay ............................................................................. 58 
4.2.5 Infectious virus yield assay ........................................................................................... 59 
4.2.6 Immunofluorescence analysis and focus-forming assay ............................................... 59 
4.2.7 Quantification of intracellular GTP concentrations ...................................................... 59 
4.2.8 RT-qPCR ........................................................................................................................ 60 
4.3 Results .................................................................................................................................. 60 
4.4 Discussion ............................................................................................................................. 64 
Chapter 5: A mutation in the hepatitis E virus RNA polymerase promotes its replication and 
associates with failure of ribavirin treatment in recipients of organ transplants ........................... 67 
5.1 Introduction .......................................................................................................................... 68 
5.2 Materials and methods......................................................................................................... 69 
5.2.1 Study subjects ............................................................................................................... 69 
5.2.2 Extraction and sequencing of HEV RNA from serum samples ....................................... 69 
5.2.3 Sanger sequencing and analysis of HEV coding regions ................................................ 70 
5.2.4 Cells, viruses and replicons ........................................................................................... 70 
5.2.5 Site-directed mutagenesis and plasmid preparation .................................................... 70 
5.2.6 In vitro transcription and capping ................................................................................. 71 
5.2.7 Antiviral assay ............................................................................................................... 71 
5.2.8 Replicon assays ............................................................................................................. 71 
5.2.9 Full-length HEV replication kinetics and competition assays ........................................ 72 
5.2.10  RT-qPCR ........................................................................................................................ 72 
5.2.11  Primers and probes....................................................................................................... 74 
5.2.12  Statistical analysis ......................................................................................................... 75 
5.3 Results .................................................................................................................................. 75 
5.3.1 Two cases of RBV treatment failure.............................................................................. 75 
5.3.2 Polymerase variants G1634R/K enhance HEV replication in a genotype 3 recombinant 
replicon assay ............................................................................................................................... 77 
5.3.3 Mutation to 1634R/K increases replication of infectious full-length genotype 3 HEV .. 78 
5 
 
5.3.4 1634R outcompetes G1634 in a viral competition assay .............................................. 80 
5.3.5 K1634 is optimal for genotype 1 HEV replication ......................................................... 81 
5.4 Discussion ............................................................................................................................. 82 
Chapter 6: mTOR-inhibitors may aggravate chronic hepatitis E .................................................... 85 
6.1 Editorial ................................................................................................................................ 86 
Chapter 7: Complete genome sequence of a rat hepatitis E virus strain isolated in the United States
 .................................................................................................................................................. 91 
7.1 Genome announcement ............................................................................................................. 92 
7.2 Nucleotide sequence accession number .................................................................................... 93 
Chapter 8: General discussion ..................................................................................................... 95 
Abstract of the research ............................................................................................................ 101 
References ................................................................................................................................ 103 
Curriculum vitae ........................................................................................................................ 123 
 
  
6 
 
  
7 
 
 
 
Dankwoord – Acknowledgements 
In de eerste plaats gaat mijn dank uit naar Professor Johan Neyts, de promotor van deze 
thesis. Bedankt, Johan, voor de kans om mijn doctoraat in uw labo te starten, voor het 
vertrouwen en de ondersteuning onderweg en uiteraard voor uw geduld met mijn 
ongeduldigheid. 
I would also like to thank Kai, my PhD mentor, for all the help and interesting discussions, 
both scientific and non-scientific. A wise man once told me that it is hard to find a good 
scientist nowadays, but at least I was lucky to have one as my mentor. 
Verder wil ik ook alle collega’s bedanken voor hun hulp, steun en aangenaam gezelschap. 
Jullie hebben zowel rechtstreeks als onrechtstreeks enorm bijgedragen aan deze thesis, 
waarvoor dank. 
Ook de leden van mijn doctoraatsthesis verdienen een woordje van dank voor hun tijd en 
inspanningen: Prof. Arthur Van Aerschot, Prof. Dominique Schols, Prof. David Cassiman, Prof. 
Etienne Sokal en Dr. Annelies Riezebos-Brilman. 
I would like to express my gratitude to the many collaborators that contributed to this 
thesis, more specifically Dr. Gerardo Kaplan, Prof. Jim Winton, Dr. Abdullah Pan, Dr. Suzanne 
Emerson, Prof. Jan Balzarini, Prof. Heiner Wedemeyer, Anett Gisa and the rest of the team in 
Hannover. 
Ook de mensen van het secretariaat verdienen een woordje van dank voor alle hulp met 
bestellingen, reizen en om zoveel andere zaken te regelen. 
Uiteraard ben ik erg veel dank verschuldigd aan mijn familie: ma, pa, oma, opa, papa, Roger, 
Angelina, Natalie, mama en natuurlijk mijn zus Tine. Bedankt! 
Ten slotte wil ik ook graag de belangrijkste JN in mijn leven bedanken. Jolien, bedankt voor 
de steun en om naar mijn eindeloze gezaag te luisteren. Je bent de beste!  
8 
 
  
9 
 
List of abbreviations 
17,20β-P 17,20β-dihydroxy-4-pregnen-3-one 
2’CMC  2’-C-methylcytidine 
4E-BP1  eIF4E-binding protein 1 
ALT  alanine aminotransferase 
ASGPR  asialoglycoprotein receptor 
AST  aspartate aminotransferase 
BVDV  bovine viral diarrhea virus 
CC  cell control 
CC50  50% cytotoxic concentration 
CHSE-214 Chinook salmon embryo cell line 214 
CPE  cytopathic effect 
CTV  cutthroat trout virus 
DMEM  Dulbecco’s modified Eagle’s medium 
DMSO  dimethylsulfoxide 
EC50  50% effective concentration 
EICAR  5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide  
eIF4E  eukaryotic initiation factor 4E 
eIF4G  eukaryotic initiation factor 4G 
ELISA  enzyme-linked immunosorbent assay 
ER  endoplasmatic reticulum 
FAM  6-carboxyfluorescein 
FBS  fetal bovine serum 
FFLuc  firefly luciferase 
GE  genome equivalents 
γGT  γ-glutamyltranspeptidase 
10 
 
GLuc  Gaussia luciferase 
HAV  hepatitis A virus 
HAVcr-1 hepatitis A virus cellular receptor 1 
HBV  hepatitis B virus 
HCV  hepatitis C virus 
HEV  hepatitis E virus 
HEX  hexachlorofluorescein 
HIV  human immunodeficiency virus 
IBFQ  Iowa black fluorescent quencher 
IC50  50% inhibitory concentration 
IFN  interferon 
IMPDH  inosine 5’-monophosphate dehydrogenase 
IRES  internal ribosome entry site 
IRF7  interferon regulatory factor 7 
IU  international units 
KIM-1  kidney injury molecule 1 
MEM  minimal essential medium 
MGB  minor groove binder 
MGBNFQ minor groove binder non-fluorescent quencher 
MIS  maturation-inducing steroid 
MMP  mycophenolate mofetil 
m.o.i.  multiplicity of infection 
MPA  mycophenolic acid 
mTOR  mammalian target of rapamycin 
MTS  3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
  2H-tetrazolium 
11 
 
OD  optical density 
ORF  open reading frame 
PABP  poly(A)-binding protein 
PBS  phosphate-buffered saline 
PEG-IFNα pegylated interferon alpha 
PI4KIIIβ phosphatidylinositol-4-kinase IIIβ 
PMS  phenazinemethosulphate 
PTB  polypyrimidine tract binding protein 
RBV  ribavirin 
RdRp  RNA-dependent RNA polymerase 
rtIFN2  rainbow trout interferon 2 
RT-(q)PCR reverse transcription (quantitative) polymerase chain reaction 
s  relative fitness gain 
SD  standard deviation 
TCID50  tissue culture infectious dose 50 
TIM-1  T-cell immunoglobulin and mucin domain-containing protein 1 
UTR  untranslated region 
VC  virus control 
wt  wild-type 
YFsfRNA yellow fever virus-derived small flaviviral RNA 
ZEN  internal quencher 
 
  
12 
 
  
13 
 
Summary 
Hepatitis A and E virus are the most prominent causes of acute viral hepatitis worldwide 
(chapter 1). Despite the availability of an effective vaccine for hepatitis A virus (HAV), it is 
widespread in developing countries and outbreaks still occur regularly in industrialized 
regions. Although most infections are asymptomatic, or have a mild clinical course, severe 
cases of hepatitis A may occur, especially in the elderly. The availability of potent and 
selective inhibitors of HAV replication would be highly appreciated for treating these severe 
cases, to reduce the duration of illness and to contain outbreaks. 
To allow for identification and development of such inhibitors of HAV replication, three 
antiviral assays were developed, including a cytopathic effect (CPE) reduction assay and two 
virus yield reduction assays for genotypes IB and IIIA (chapter 2). The assays were validated 
with two known inhibitors of HAV replication: interferon alpha (IFNα) effectively inhibited 
virus replication, while the activity of amantadine HCl proved to be strain-dependent. In 
addition, the effect of the enterovirus inhibitors pleconaril, rupintrivir and enviroxime on 
HAV replication was assessed. Pleconaril exhibited some very moderate activity, whereas the 
effect of rupintrivir proved to be strain-dependent. Enviroxime did not inhibit HAV 
replication, suggesting that phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) is not crucial in the 
HAV life cycle. 
Similar to HAV, hepatitis E virus (HEV) is transmitted feco-orally. Consequently, large 
outbreaks are often reported in refugee camps, e.g. in Africa. Infections are often 
asymptomatic or mild, although severe infections may occur, especially in pregnant women. 
Chronic cases of hepatitis E have also been described in immunocompromised patients (such 
as transplant recipients) with a high risk for cirrhosis and liver failure. HEV infections can be 
treated with a extended ribavirin (RBV) regimen which seems mostly effective, although 
cases of treatment failure have been reported and side effects may be severe. Consequently, 
there is a need for more potent non-toxic inhibitors of HEV replication and for 
characterization of the currently used RBV treatment regimen. 
First, an antiviral assay was developed using the HEV-related cutthroat trout virus (CTV) as a 
surrogate virus (chapter 3). RBV and trout IFN were found to efficiently inhibit CTV 
replication, while other known broad-spectrum inhibitors of RNA virus replication such as 
the nucleoside analog 2’-C-methylcytidine resulted only in a moderate antiviral activity. In 
addition, CTV is only detected in trout during spawning, which suggests a hormonal influence 
on viral replication and is reminiscent of the high susceptibility of pregnant women to severe 
hepatitis E. Consequently, the effect of three sex steroids on in vitro CTV replication was 
evaluated. Whereas progesterone resulted in marked inhibition of virus replication, 
testosterone and 17β-estradiol stimulated viral growth. Our data thus indicate that CTV may 
serve as a surrogate model for HEV. 
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Next, the in vitro culturable HEV strain Kernow-C1 p6 and a derived subgenomic replicon 
were used to develop antiviral assays for the genuine HEV (chapter 4). Thus it was confirmed 
that IFNα and RBV inhibit in vitro HEV replication. A moderate but significant synergism was 
observed for combinations of both drugs. These findings corroborate the reported clinical 
effectiveness. In addition, the in vitro mechanism of action of RBV was studied and was 
found to depend on depletion of intracellular GTP pools. 
Since cases of RBV treatment failure have been described, a collaboration was initiated with 
the clinical reference laboratory for hepatitis E in Hannover, Germany (chapter 5). We 
analyzed blood samples collected from 15 patients with chronic hepatitis E who were 
recipients of solid-organ transplants and were treated with RBV. All patients cleared the 
virus except for two non-responders of which one patient died. A G1634R mutation in the 
viral polymerase was detected in the HEV RNA of the non-responders; this mutation did not 
provide the virus with resistance to RBV in vitro. However, the mutant form of a subgenomic 
replicon of genotype 3 HEV replicated more efficiently in vitro than HEV without this 
mutation, and the same was true for infectious virus, including in competition assays. Similar 
results were obtained for genotype 1 HEV. The G1634R mutation therefore appears to 
increase the replicative capacity of HEV in the human liver and hence reduce the efficacy of 
RBV. 
In a recent paper by Zhou and colleagues, a stimulating effect of mammalian target of 
rapamycin (mTOR)-inhibitors such as rapamycin and everolimus on HEV replication was 
described.1 In chapter 6, we discuss these observations, including clinical implications and 
possible underlying mechanisms, in an Editorial. 
Finally, chapter 7 comprises the announcement of the first complete genome sequence of a 
US isolate of rat HEV. This is a first step towards the implementation of a convenient small 
animal model for hepatitis E. 
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Samenvatting 
Hepatitis A en E virus zijn wereldwijd de voornaamste oorzaken van acute virale hepatitis 
(hoofdstuk 1). Ondanks de beschikbaarheid van een effectief vaccin tegen het hepatitis A 
virus (HAV), is het virus endemisch in ontwikkelingslanden en vinden er nog geregeld 
uitbraken plaats in geïndustrialiseerde regio’s. Hoewel de meeste infecties asymptomatisch 
zijn of een mild klinisch verloop kennen, komen er toch ernstige gevallen van hepatitis A 
voor, vooral bij ouderen. De beschikbaarheid van potente en selectieve inhibitoren van HAV 
replicatie zouden erg nuttig zijn in de behandeling van ernstige gevallen, maar ook om de 
ziekteduur te verkorten en uitbraken snel in te perken. 
Om de ontwikkeling en identificatie van zulke inhibitoren van HAV replicatie mogelijk te 
maken, werden er drie antivirale testen ontwikkeld, waaronder een cytopathisch-effect-
reductie-assay en twee virusopbrengst-reductie-assays voor genotypes IB en IIIA (hoofdstuk 
2). De testen werden gevalideerd met twee gekende inhibitoren van HAV replicatie: 
interferon alfa (IFNα) inhibeerde de virusreplicatie efficiënt, terwijl de activiteit van 
amantadine HCl stamafhankelijk bleek te zijn. Ook werd het effect van remmers van 
enterovirusreplicatie (pleconaril, rupintrivir en enviroxime) op HAV replicatie bestudeerd. 
Pleconaril vertoonde een erg matige activiteit, terwijl het effect van rupintrivir stam-
afhankelijk bleek. Enviroxime inhibeerde de HAV replicatie niet, wat suggereert dat 
fosfatidylinositol-4-kinase IIIβ (PI4KIIIβ) niet cruciaal is in de HAV-replicatiecyclus. 
Gelijkaardig aan HAV, wordt het hepatitis E virus (HEV) feco-oraal overgebracht. Zo worden 
er regelmatig grote uitbraken gerapporteerd in vluchtelingenkampen, bijvoorbeeld in Afrika. 
Infecties zijn vaak asymptomatisch of mild, maar ernstige infecties kunnen voorkomen. In 
zwangere vrouwen kan de mortaliteit oplopen tot 25%. Ook chronische gevallen van 
hepatitis E zijn beschreven in immuungecompromitteerde patiënten (zoals 
transplantpatiënten). Deze patënten hebben een hoog risico voor de ontwikkeling van 
cirrose en leverfalen. HEV infecties kunnen behandeld worden met een 
weken/maandenlange toediening van ribavirine (RBV). Dit is meestal succesvol, maar er zijn 
gevallen van therapiefalen gerapporteerd zijn en de neveneffecten ernstig kunnen zijn. 
Bijgevolg is er nood aan potentere, niet-toxische inhibitoren van HEV replicatie en aan een 
grondige studie van het huidige RBV-behandelingsschema. 
Ten eerste werd er een antivirale test ontwikkeld met het aan-HEV-verwante “Cutthroat”-
forel-virus (CTV) als surrogaatvirus (hoofdstuk 3). RBV en forel-IFN bleken de replicatie van 
CTV efficiënt te inhiberen, terwijl andere gekende breedspectruminhibitoren van RNA-virus-
replicatie (zoals het nucleosideanaloog 2’-C-methylcytidine) enkel een matige antivirale 
activiteit vertoonden. CTV wordt enkel gedetecteerd in forel tijdens het kuit schieten, wat 
een hormonaal effect op virale replicatie doet vermoeden, net zoals bij de verhoogde 
gevoeligheid van zwangere vrouwen aan genotype 1 HEV. Daarom werd het effect van drie 
geslachtshormonen op in vitro CTV replicatie geëvalueerd. Terwijl progesteron een 
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duidelijke inhibitie van virusreplicatie vertoonde, stimuleerden testosteron en 17β-estradiol 
de virusgroei. Op basis van onze data kan geconcludeerd worden dat CTV als een 
surrogaatmodel voor HEV kan dienen. 
Vervolgens werden de in-vitro-replicerende HEV stam Kernow-C1 p6 en een afgeleid 
subgenomisch replicon gebruikt om anti-HEV assays te ontwikkelen (hoofdstuk 4). Gebruik 
makend van deze assays, toonden we aan dat IFNα en RBV de in-vitro-HEV-replicatie 
inhiberen. Ook werd er een matige, maar significante synergie geobserveerd voor 
combinaties van beide geneesmiddelen. Deze bevindingen bevestigen de gerapporteerde 
klinische werkzaamheid. Daarenboven werd het in-vitro-werkingsmechanisme van RBV 
bestudeerd, dit bleek afhankelijk te zijn van de uitputting van intracellulaire GTP-voorraden. 
Aangezien gevallen van RBV-therapiefalen beschreven zijn, werd een samenwerking opgezet 
met het klinisch referentielabo voor hepatitis E in Hannover, Duitsland (hoofdstuk 5). We 
analyseerden bloedstalen afkomstig van 15 patiënten met chronische hepatitis E die eerder 
een orgaantransplantatie ondergingen en behandeld werden met RBV. Alle patiënten 
elimineerden het virus, behalve twee waarvan één patiënt stierf. Een G1634R mutatie in het 
viraal polymerase werd gedetecteerd in het HEV RNA van de niet-responders. Deze mutatie 
resulteerde verrassend genoeg niet in in-vitro-resistentie tegen RBV. De mutante vorm van 
een subgenomisch replicon van genotype 3 HEV repliceerde daarentegen wel efficiënter in 
vitro dan het wild-type replicon. We konden dit ook bevestigen gebruik makend van het 
volledig, infectieus virus, ook in competitietesten. Gelijkaardige resultaten werden bekomen 
voor genotype 1 HEV. De G1634R mutatie lijkt daarom de replicatiecapaciteit van HEV in de 
humane lever te bevorderen en op die manier de werkzaamheid van RBV te verminderen. 
In een recente publicatie1 werd een stimulerend effect voor inhibitoren van het mammalian 
target of rapamycin (mTOR) beschreven. In hoofdstuk 6 bespreken we deze bevindingen (in 
een editoriaal), inclusief klinische implicaties en mogelijke onderliggende mechanismen. 
Ten slotte behandelt hoofdstuk 7 de aankondiging van de eerste, volledige, genomische 
sequentie van een US isolaat van rat HEV. Dit is een eerste stap in de ontwikkeling van een 
geschikt (knaag)diermodel voor hepatitis E. 
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This chapter contains parts of the following published papers: 
Debing Y, Jochmans D, Neyts J. 2013. Intervention strategies for emerging viruses: use of 
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Med Res Rev 34:895-917. 
Debing Y, Neyts J. 2014. Antiviral strategies for hepatitis E virus. Antiviral Res 102:106-118. 
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1.1 Hepatitis A virus 
HAV is a major cause of enterically-transmitted hepatitis worldwide, posing a global burden 
estimated in 2005 at 119 million infections of which 31 million resulted in symptomatic 
illness and 34 000 in death.2 The virus is transmitted feco-orally, mainly through close 
contact with infected individuals or by consumption of contaminated food and drinking 
water. The extreme environmental stability of the HAV particle contributes significantly to its 
transmission.3,4 HAV epidemiology correlates with poor hygiene and living conditions. 
Consequently, virtually every adult in developing countries is seropositive due to childhood 
infection. On the contrary, in regions with improved hygiene standards, infection is often 
postponed to later age. In addition, disease severity is generally age-dependent: infections 
are usually mild or asymptomatic in young children, whereas at older age, hepatitis A 
frequently presents with classic symptoms of acute hepatitis (e.g. jaundice, fatigue, general 
malaise,…) and a higher incidence of fulminant hepatitis, which may require liver 
transplantation.5 Fulminant hepatitis occurs especially in those aged over 50 for which 
mortality rates up to 5.4% have been reported.6 Additionally, HAV superinfections in chronic 
liver disease patients (e.g. hepatitis B or C) are believed to increase morbidity and 
mortality,7–9 although these findings are still subject to debate.10 Since highly efficient 
vaccines that provide long-lasting immunity have become available, HAV mortality and 
morbidity has decreased dramatically.9,11 However, occasional outbreaks of hepatitis A, 
sometimes resulting in fatal outcomes, still occur in industrialized countries. For instance, in 
the last decade, outbreaks have been linked to the consumption of contaminated green 
onions, semi-dried tomatoes, seafood, such as raw oysters and sushi, and other 
foodstuffs.12–15 
As posited earlier,16 research interest in the molecular biology and pathogenesis of HAV has 
decreased substantially since the availability of a safe and efficient vaccine. Nonetheless, 
HAV remains an intriguing and poorly understood virus and hepatitis A is still a public health 
problem in many countries. In this introduction, key aspects of the biology of HAV will be 
reviewed with an emphasis on recent findings and the unique characteristics of the virus. 
The potential clinical use of antivirals against HAV will be discussed as well. 
1.1.1 HAV genome organization and replication cycle 
HAV is a non-enveloped, single-stranded RNA virus with a positive-sense genome. Despite 
the fact that HAV is classified within the family of the Picornaviridae, it exhibits quite some 
differences compared to other members of this family and is consequently the sole member 
of the genus Hepatovirus (http://ictvonline.org/virusTaxonomy.asp). Based on phylogenetic 
analysis of full length VP1 sequences, the single HAV serotype is divided into 6 genotypes (I-
VI).17 Genotypes I to III are human and can be subdivided into subgenotypes A and B (and 
potentially subgenotype IC),18 whereas genotypes IV to VI are of simian origin.17 The HAV 
genome (as shown in figure 1.1) is approximately 7.5kb in length and consists of a 5’ 
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untranslated region (UTR), a single open reading frame (ORF) and a 3’-UTR with a 
polyadenosine-tract. Like other picornaviruses, the HAV genome lacks a cap structure; 
instead a VPg protein (3B) is attached to the 5’ end. In the 5’-UTR, six secondary structure 
domains can be found: domain I contains a hairpin structure, while the second domain 
comprises two stem loop structures followed by a polypyrimidine tract (pY1).19 The 
remaining domains form the type III internal ribosome entry site (IRES) allowing cap-
independent translation of the viral genome. The single ORF comprises the structural genes 
(VP1 to VP4 (=P1) and 2A) and the non-structural genes (2B-C and 3A-D). The short 3’-UTR 
contains two stem loops and/or a pseudoknot structure which are, together with domains I 
and II and the polypyrimidine tract of the 5’-UTR, crucial for viral RNA synthesis.20 
Figure 1.1 HAV genome organization and proteolytic processing of the structural proteins 
(IRES, internal ribosome entry site; UTR, untranslated region) 
1.1.1.1 Receptor binding and cell entry 
In 1996, the HAV cellular receptor (HAVcr-1) was identified on African green monkey kidney 
cells as an attachment and probably functional receptor.21 Consequently, the human 
homolog was identified and characterized as a human HAV receptor.22 HAVcr-1 is also 
known to be a marker for acute ischemic kidney injury (in this context referred to as kidney 
injury molecule 1 or KIM-1)23 and a regulator of T-cell based immunity (in this context 
referred to as T-cell immunoglobulin and mucin domain-containing protein 1 or TIM-1).24 
Nevertheless, since HAVcr-1 is also expressed on other organs,22 it is likely that additional 
receptors are required for HAV attachment and entry. For instance, it has been suggested 
that TIM-3 promotes HAV entry without being a functional receptor.25 In addition, HAV-
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specific IgA are reported to mediate infection of hepatocytes via the asialoglycoprotein 
receptor (ASGPR).26 This and the fact that IgA was also identified as a natural ligand for 
HAVcr-127 may explain why (and how) IgA-coated HAV can enter the hepatocytes through 
both HAVcr-1 and ASGPR, thereby promoting enterohepatic circulation and continuous 
(endogenous) reinfections of the liver.28 This phenomenon is thought to play an essential 
role in prolonged and relapsing cases of hepatitis A. Only the emergence of avid IgG 
antibodies can break the cycle and eventually clear the infection.28 
1.1.1.2 Uptake and uncoating 
Following receptor-mediated binding to the cell surface, the HAV particle is internalized. This 
has been suggested to occur through receptor-mediated endocytosis since HAV infection can 
be inhibited by blockers of endosomal acidification such as monensin, ammonium chloride 
and chloroquine.29–32 However, the precise mechanism remains unclear to date. Upon 
binding to its receptor the particle is destabilized, thus initiating the uncoating process and 
releasing the single-stranded RNA into the host cell cytoplasm.33 Uncoating has been 
reported to be a slow and asynchronous process with a reported duration of 4 to 10 hours, 
in contrast to under an hour for poliovirus.34 It has been proposed that this asynchronicity 
may be due to the fact that the HAV inoculum contains a heterogeneous mixture of mature 
virions and provirions. These provirions still require a maturation cleavage (of VP0 into VP2 
and VP4, as discussed below) following entry, prior to uncoating, and might therefore uncoat 
more slowly than mature virions.34,35 During the uncoating process, dense, non-infectious 
HAV uncoating intermediates are formed. Intriguingly, these particles do not appear to have 
an altered sedimentation profile, thereby differing from the typical picornaviral A particle.36 
Finally, both low pH and Ca2+ ions are reported to play an important role in HAV receptor 
binding, uncoating and during the maturation cleavage of provirions following virus entry (as 
described above).31,32,35,37 Upon completion of uncoating, the single-stranded RNA is 
released into the host cell by an unknown mechanism. 
1.1.1.3 Translation 
The viral RNA, being released into the cytoplasm, is then translated into a single polyprotein. 
Similar to other picornaviruses, HAV employs an IRES, located in the 5’ UTR, to direct cap-
independent translation of the viral genome using the host ribosomal machinery. Most 
picornaviruses affect the host cell protein synthesis to favor a more efficient translation of 
the viral mRNA. This process is mediated by a proteolytic cleavage of eukaryotic initiation 
factor 4G (eIF4G), thereby inducing a complete shut-down of capped mRNA translation.38 
Intriguingly, unlike for other picornaviruses, it is thought that HAV IRES depends on eIF4G, as 
part of an intact eIF4F complex.39 The fact that HAV has to compete with an intact host cell 
machinery may also explain its poor replication in cell culture (see section 1.2). However, a 
recent publication by Redondo et al. suggested that HAV IRES-driven translation can occur 
without intact eIF4G and that another factor may be crucial for this translation.38 
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Next, the translated polyprotein is processed co- and posttranslationally in a series of 
proteolytic cleavages into several functional precursor and mature proteins. The primary 
posttranslational cleavage occurs at the junction between P1-2A and 2B (instead of the 
junction between P1 and 2A as for other picornaviruses) (figure 1.1).40 All other processing 
steps (except the VP1-2A junction, as discussed below) are mediated by 3Cpro and its 
functional precursor 3ABCpro.41 This is different from other picornaviruses which may use 
Lpro, 2A, 3Cpro and the 3CDpro precursor.42 Intriguingly, HAV protein 2A, unlike for other 
picornaviruses, has no proteolytic activity nor does it contain a ribosome-skipping 
sequence,42 but seems to be implicated in morphogenesis (see section 1.1.1.6). 
1.1.1.4 Regulating the balance between translation and replication  
Since translation of viral proteins and RNA replication are competing processes, they must 
be balanced properly to allow efficient viral replication.43 In order to tip the balance from 
translation to replication, the poly(A)-binding protein (PABP), as part of the eIF4F complex, is 
cleaved by HAV 3Cpro. The N-terminal cleavage product of PABP was shown to have an 
improved RNA-binding capacity compared to uncleaved PABP and may act as a dominant 
negative for IRES-mediated translation, thus favoring viral RNA synthesis.44 Additionally, 
proteolytic cleavage of the poly(rC)-binding protein PCBP2, which interacts with the 
pyrimidine-rich tract pY1 in the HAV 5’-UTR, may also be implicated in regulating the balance 
between translation and viral RNA synthesis.19 Other enzymes that bind to the HAV IRES are 
polypyrimidine tract binding protein (PTB), glyceraldehyde 3-phosphate dehydrogenase and 
La autoantigen that respectively enhance, suppress and suppress translation.45–47 
1.1.1.5 Replication 
As for most RNA viruses, replication of the viral genome takes places in replication 
complexes that consist of rearranged cellular membranes containing both viral and host 
proteins. Studies revealed important roles for 2BC precursor and 2C proteins in the 
membrane rearrangements forming the replication complexes. These complexes are 
described as a tubular vesicular network and were thought to be of endoplasmatic reticulum 
(ER) origin.48,49 However, a recent publication described the mitochondrial localization of the 
3ABC precursor protein suggesting that HAV replication complexes may be derived from the 
outer mitochondrial membrane.50 In line with this hypothesis, exchanging the mitochondria-
targeting 3A transmembrane domain for the ER-targeting poliovirus 3A transmembrane 
domain resulted in loss of replication competence.51 
Within the replication complexes, the viral genome is transcribed into antisense RNA which 
subsequently serves as a template for the production of new viral genomes. During this 
process, the 3D protein functions as an RNA-dependent RNA polymerase (RdRp). The 3B 
(VPg) protein serves as a starting point for primer-independent transcription and is 
covalently linked to the 5’ genome end. A conserved replication element near the 5’ end of 
the 3Dpol-coding sequence likely directs uridylylation of VPg by 3Dpol, in such way priming 
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VPg for initiation of RNA replication.52 During replication, the 3A/3B junction remains 
uncleaved and the transmembrane protein 3A serves as an anchor tethering the growing 
HAV RNA strand and associated proteins to the membranes of the replication complex,42,53 
as is the case for other picornaviruses.54 It has also been reported that the 2C protein of HAV 
binds to the 3’ end of the antisense RNA. In this way protein 2C may be implicated in 
anchoring the negative sense RNA template to the membranes of the replication complex.55 
1.1.1.6 Capsid assembly 
Despite the fact that the multi-tiered capsid assembly process is only poorly understood, 
HAV differs at various steps from other picornaviruses. Following the initial cleavage at the 
2A/2B junction by 3Cpro (as discussed above), the N-terminal part of protein 2A coordinates 
proper folding of the P1-2A precursor protein. This precursor protein is then processed by 
3Cpro and its stable precursor 3ABCpro into VP0 (consisting of VP4 and VP2), pX precursor 
(consisting of VP1 and 2A) and mature VP3 protein.42,56 These building blocks assemble into 
pentamers and subsequently associate with viral RNA to form preprovirions. In a final 
processing step, VP0 will be cleaved into VP4 and VP2 and precursor pX into VP1 and 2A, 
yielding mature virus particles with only VP1, VP2 and VP3 proteins. The processing of pX is 
mediated by a yet unknown cellular protease.57 Although the cleavage can be performed by 
extracellular enzymes like factor Xa and trypsin,58,59 maturation can also be executed by the 
lysosomal proteinase cathepsin L. This may indicate a role for lysosomal proteinases in 
maturation cleavage and potential targeting of HAV provirions to the early lysosomes for 
maturation cleavage.59 On the other hand, VP0 processing is thought to be a self-catalytic 
process that is dependent on the presence of encapsidated RNA.60 The resulting VP4 is 
rather small compared to other picornaviruses and lacks an N-terminal myristoylation 
signal.61 Note that the mature VP4 protein has never been identified in purified virus stocks 
and its role in capsid formation remains unclear.16,60 
1.1.1.7 Release 
HAV is an enterically transmitted virus that replicates mostly in hepatocytes before it is 
excreted via the bile into the feces. Despite the fact that the exact details of HAV release 
remain elusive, the mechanism seems to differ depending on the cell type infected and is 
thought to involve either a vesicle-mediated cellular protein transport pathway or 
specialized hepatocellular transport proteins involved in bile secretion.62 Blank and 
colleagues demonstrated that following infection of polarized human intestinal epithelial 
Caco-2 cells, release of progeny virus was largely restricted to the apical membrane.62 In this 
way, virus is secreted mainly into the intestinal lumen resulting in an amplification of the 
HAV inoculum in the intestines and thus an increased viral shedding and spreading of the 
virus. However, it is still unclear by which mechanism HAV reaches the blood stream. A role 
for transcytosis by M cells present in Peyer’s patches in the ileum has been suggested, a 
mechanism that was found for poliovirus and reovirus as well.62 Another study described 
that infection of polarized human hepatocytes occurred most efficiently via the basolateral 
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plasma membrane, after which more than 95% of progeny virus was exported through the 
basolateral membrane (into the bloodstream), rather than through the apical membrane 
(into the bile channels).63 This contrasts with the in vivo observation that bile and fecal titers 
are considerably higher than serum titers.16,64 Reuptake and transcytosis of progeny virus by 
the hepatocytes into the bile channels is suggested as the mechanism for enteric secretion. 
1.1.1.8 Particle structure 
HAV is a non-enveloped icosahedral particle of approximately 27 nm in diameter.65 The 
mature capsid is composed of 12 pentamers each consisting of 5 copies of VP1, VP2 and VP3. 
Unlike for other picornaviruses, VP4 appears not to be present in mature HAV particles (see 
section 1.1.1.6). Attempts to produce high-resolution images of HAV particles remained 
unsuccessful so far. A 2006 review16 showed a medium-resolution image obtained by cryo-
electron microscopy suggesting the absence of the well-defined canyon surrounding the 5-
fold axis, in this way differing from other picornaviruses. However, these results have not 
been confirmed or published separately to date. HAV has a limited number of neutralization 
antigenic sites. The immunodominant antigenic site is composed of VP1 and VP3 residues 
and is conformation-dependent.66 A second antigenic site is the glycophorin A binding site by 
which HAV can bind to erythrocytes, causing hemagglutination. This process is optimal at 
acidic pH, but is impaired at physiological pH. This suggests that HAV has evolved to escape 
erythrocyte binding and consequent clearance.67,68 Indeed, a mutant of this binding site 
displayed increased clearance from the blood and lower overall fitness, suggesting 
evolutionary constraints and explaining the low level of antigenic variability of the 
glycophorin A binding site.68 
1.1.2 Cell culture 
Unlike for most picornaviruses, culturing wild-type (wt) HAV in cell culture has proven to be 
quite a challenge as these strains replicate only very marginally in vitro (e.g. reference 69). 
HAV can be adapted to growth in cell culture through serial passaging; a process that 
introduces cell culture-adapting mutations stepwise into the viral genome. Such mutations 
have been found in the P2 region (especially in 2B and 2C)70,71 and in the 5’-UTR,72,73 but also 
in other parts of the genome.70 Intriguingly, these cell culture-adapting mutations result in 
HAV strains that are highly attenuated in vivo (e.g. references 71,72). A major advance in 
culturing HAV was the selection of a Huh7 cell line (designated Huh7-A-I) which allows 
genetically stable growth of wt HAV without the accumulation of cell culture-adapting 
mutations.74 Nevertheless, this implies that virtually all information regarding the HAV 
replication cycle has been derived from studies employing cancer cell lines and remains to 
be confirmed in bona fide hepatocytes. 
Although wt HAV does not induce CPE in cell culture, cytopathic strains may arise during 
prolonged serial passaging.75,76 CPE appears to be cell type-specific and is mostly found in 
monkey kidney cell lines like FRhK-4 and BS-C-1. These selected virus strains induce 
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apoptosis through ribosomal RNA degradation by RNase L77,78 and consequent caspase 
activation.79 Interestingly, it seems possible to induce CPE with cell culture-adapted non-
cytopathic strains under specific conditions of lower temperature (<34°C) and decreased cell 
density, both in FRhK-4 and human A549 cells.80 Similarly, we observed CPE for the PA21 
strain (genotype IIIa) in FRhK-4 cells under these conditions (unpublished results). 
1.1.3 The need for antivirals? 
Despite the availability of an efficient vaccine, an antiviral drug against HAV would be of 
great use. First, since HAV growth in vitro is rather limited, the production of vaccines 
remains a painstaking process which in part explains the high cost.16 This cost is particularly a 
problem in relatively poor regions with improved hygiene where infections occur at later age 
and consequently are more severe.5 Second, antivirals could shorten the period of illness 
and decrease symptoms and associated economic costs in infected unvaccinated patients. 
Early treatment of these infected unvaccinated persons may also prevent severe cases of 
fulminant hepatitis. Third, an antiviral could be a useful tool in rapidly containing epidemics. 
Lastly, the potential emergence of vaccine-escape variants has been reported recently;18 an 
anti-HAV drug could therefore be instrumental in halting the spread of such virus strains. In 
conclusion, there is certainly a need for antiviral drugs for hepatitis A, given that they are 
safe, efficacious and preferably cheap. 
1.2 Hepatitis E virus 
HEV is a feco-orally transmitted pathogen and one of the most common causes of acute 
hepatitis worldwide. Although the virus was already identified in 1983,81 many of its 
epidemiological and clinical features are becoming clear just recently. HEV is responsible for 
both acute outbreaks in developing countries and sporadic cases worldwide and is more and 
more being recognized as a problem in the transplant setting.82,83 Although most infections 
are self-resolving, hepatitis E is characterized by a high mortality in pregnant women and can 
lead to chronic infections in immunocompromised patients. A vaccine has recently been 
approved for the Chinese, but not for other markets.84 Current therapeutic options (i.e. RBV 
and IFNα) have severe side effects and treatment failure has been reported. It may be 
important to have potent and safe inhibitors of HEV replication at hand to rapidly contain 
outbreaks and to treat immunodeficient patients. 
1.2.1 HEV molecular virology 
1.2.1.1 Genome structure 
HEV has a capped positive-sense single-stranded RNA genome that comprises a 5’-UTR, ORFs 
1–3 and a 3’-UTR followed by a polyA-tract (see figure 1.2). ORF1 encodes the non-structural 
proteins and contains methyltransferase, protease, macrodomain, helicase and RdRp-
encoding sequences.85 Between the protease and the macrodomain, a hypervariable region 
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containing a proline-rich hinge was found.86 The overlapping ORFs 2 and 3 are translated 
from a single subgenomic RNA into the structural proteins.87 ORF2 encodes the 660-aa 
capsid protein that consists of a shell domain (S), a middle domain (M, also called P1) and a 
protruding domain (P, also called P2).88,89 The protein translated from ORF3 is 114 aa in 
length, is phosphorylated90 and unique to HEV and closely related viruses. 
Figure 1.2 Organization of the HEV genome. Non-structural proteins are translated from 
ORF1 while the ORF2 and ORF3 structural proteins are translated from a single subgenomic 
RNA. UTR, untranslated region; Y, Y-domain; PCP, papain-like cysteine protease; HVR, 
hypervariable region; X, macro domain; RdRp, RNA-dependent RNA polymerase. 
1.2.1.2 Replication cycle 
Although understudied, the HEV replication cycle seems typical for a single-stranded RNA 
virus of positive polarity (see figure 1.3). The virus particle first binds to heparan sulfate 
proteoglycans on the host cell membrane,91 transfers to its (unknown) cellular membrane 
receptor(s) and the resulting complex is internalized through clathrin-mediated 
endocytosis.92 Consequently, the capped viral genome is released from the virion during the 
uncoating process and directly translated by the host cell ribosomal machinery. The non-
structural proteins thus generated allow for the replication of the viral genome (probably in 
specific viral replication complexes) and the production of subgenomic RNA that is translated 
into the structural proteins from ORF2 and ORF3. Full-length RNA progeny is assembled with 
ORF2 capsid protein into viral particles of 27–30 nm81 that are consequently released from 
the cell in a non-lytic fashion. During release, HEV particles probably acquire a lipid bilayer 
(envelope) and associated ORF3 protein that are removed later by bile salts and enteric 
proteases respectively.93,94 These limited insights into HEV replication have been obtained 
using hepatoma cell lines and should ideally be confirmed in primary hepatocytes. 
The available information on host factors involved in HEV replication and pathogenesis is 
very limited to date. Tumor susceptibility gene 101 (Tsg101) is known to be involved in virion 
release (see figure 1.3),95 while recent studies suggest that mTOR and calcineurin may be 
involved in antiviral pathways, although the underlying mechanisms have not been 
completely elucidated yet.1,96 
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Figure 1.3 HEV replication cycle. HEV particles first bind to heparan sulphate proteoglycans 
(HSPG) and are consequently transferred to an unknown functional receptor, thus mediating 
cellular uptake through clathrin-mediated endocytosis. Following uncoating, the viral RNA 
genome is released into the cytoplasm and translated into nonstructural proteins. These 
proteins form a replication complex that produces new full-length and subgenomic viral RNA. 
The latter is translated into capsid protein (ORF2) and the membrane associated ORF3 
protein that is known to interfere with interferon-a signaling. Viral RNA is packaged into 
capsid protein and released from the cell with help of the host factor Tumor susceptibility 
gene 101 (Tsg101). The released particles are associated with lipids and ORF3 proteins; both 
are consequently removed through the bile acids and digestive proteases respectively. 
1.2.1.3 Genetic diversity 
HEV is classified into the Hepevirus genus in the family of the Hepeviridae 
(http://ictvonline.org/virusTaxonomy.asp). At least 4 genotypes are currently recognized;97 
genotypes 1 and 2 solely infect humans while genotypes 3 and 4 are zoonotic agents with 
their main reservoir in domestic pigs.98–100 Two additional genotypes have been proposed for 
HEV isolates from Japanese wild boars.97 Several viruses that are more or less related to HEV 
have been isolated from different species, including chickens (avian HEV),101 rabbits,102 
rats,103 bats,104 ferrets105 and trout106 (figure 1.4). The exact classification of these viruses 
remains to be determined97 and future discovery of additional hepeviruses seems likely. 
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Figure 1.4 HEV species and genotypes. The phylogenetic relationship of different human HEV 
genotypes and the reported animal strains was plotted with the Virus Pathogen Database 
and Analysis Resource (ViPR)107 based on following sequences: HEV gt1 (GenBank accession 
No. M80581), HEV gt2 (M74506), HEV gt3 (HQ389543), rabbit HEV (FJ906895), HEV gt4 
(AB220973), wild boar HEV 2006 (AB602441), wild boar HEV 2009 (AB573435), ferret HEV 
(JN998606), rat HEV (GU345043), bat HEV (JQ001749), avian HEV (AY535004), CTV 
(HQ731075). gt, genotype. 
1.2.2 Hepatitis E 
1.2.2.1 Epidemiology of disease 
HEV genotypes 1 and 2 only infect humans and are endemic in many developing regions 
where they tend to cause large-scale water-borne outbreaks.108,109 Genotype 1 is mainly 
found in Asia and Africa,110,111 while genotype 2 has been isolated from Mexico and Africa, 
but seems less common.112,113 It is estimated that infections with these genotypes result in 
70 000 deaths annually.114 Genotypes 3 and 4 on the other hand are zoonotic agents with 
their main reservoir in domestic pigs.115–117 Genotype 3 has a worldwide distribution, while 
genotype 4 is mostly found in Asia.118,119 However, genotype 4 has also been isolated from 
European pigs and patients recently.120,121 Genotype 3 and 4 infections often result from 
consumption of undercooked pig or deer meat and may thus cause sporadic cases of 
hepatitis E. Although exact epidemiological data are missing, these infections seem a lot 
more common than initially thought.122–124 
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1.2.2.2 Clinical syndromes 
Acute hepatitis E is characterized by jaundice, fatigue, gastrointestinal discomfort, etc. and is 
clinically indistinguishable from for instance hepatitis A,125 although many infections remain 
asymptomatic. Most cases of hepatitis E resolve spontaneously, but in some patients the 
infection may progress to fulminant hepatitis. Overall mortality rates are estimated between 
0.5% and 4% (e.g. 111,125). One particularly intriguing characteristic is that hepatitis E is often 
lethal in pregnant women with mortality rates of up to 20–25%,126,127 although this has only 
been observed for genotype 1 infections. Increased frequencies of obstetric complications 
and stillbirths have also been reported.128 The underlying mechanisms of this phenomenon 
(hormonal, immunological, genetic factors, etc.) are unclear to date. 
A more recent finding is that HEV can establish chronic infections in immunocompromised 
subjects such as transplant and HIV-infected patients.129–131 This has only been reported for 
genotype 3 thus far. Such chronic infections are rarely symptomatic and are sometimes 
mistaken for drug-induced liver injury.132 Chronic hepatitis E may lead to cirrhosis in 10% of 
patients133 and can ultimately result in death. 
Occasional extrahepatic manifestations have also been reported; these are mostly 
neurological complications such as Guillain–Barré syndrome and neuralgic amyotrophy134–136 
or nefrological manifestations such as glomerulonephritis.137 
As evident from the discussion above, hepatitis E is profoundly different from the well-
known disease courses of hepatitis B and C. While a considerable portion of patients 
infected with the hepatitis B virus (HBV) and especially the hepatitis C virus (HCV) evolves to 
chronicity, spontaneous recovery is the rule for hepatitis E where chronic disease has thus 
far only been reported in immunocompromised patients. The high rate of mortality in 
pregnant women is also unique to hepatitis E and no similar phenomena have been reported 
for hepatitis A, B or C. 
1.2.2.3 Diagnostic methods 
The most frequently used tests for diagnosing hepatitis E are detection of IgM and IgG 
antibodies by enzyme-linked immunosorbent assays (ELISA) and detection of viral RNA by 
(quantitative) reverse transcription PCR (RT-(q)PCR). Presence of IgM antibodies indicates a 
recent infection, while IgG antibodies appear later and persist afterwards, at least for some 
time, indicating a past exposure. The current ELISAs suffer from large variability between 
assays138–140 and therefore require urgent optimization and validation. Acute infection is 
usually confirmed by (quantitative) RT-PCR (e.g. 141), although these assays should be 
standardized as well to increase reliability. 
Since the incubation and symptomatic periods for acute hepatitis E are only a few weeks, the 
successful use of antiviral drugs for acute cases of hepatitis E would depend on the 
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availability of a rapid and inexpensive diagnostic test. Such test should also be easy to 
employ in resource-poor settings. 
1.2.3 Current control strategies 
1.2.3.1 Vaccines 
Vaccination would be an effective strategy to prevent HEV infection. Recently, such a HEV 
vaccine based on a recombinant truncated capsid protein was approved in China 
(Hecolin®).84 It remains unclear whether the manufacturer intends to obtain market 
approval in other countries as well. Another recombinant vaccine successfully completed 
phase 2 clinical trials in Nepal,142 but further development was halted. Such vaccines may be 
useful as a prophylactic measure in high-risk patients such as immunocompromised patients 
and pregnant women. This would require specific clinical trials to demonstrate protective 
efficacy in these populations; to the best of our knowledge, such studies have not yet been 
reported for Hecolin®. However, the organization of large-scale vaccination campaigns 
against HEV may not be particularly cost-effective given the mostly benign course of 
infection in developing countries and the relatively low incidence in the developed world. 
1.2.3.2 Other prophylactic measures 
Since HEV is transmitted feco-orally, sanitary measures are probably the most effective 
strategy available to prevent viral spread. This is especially the case for genotypes 1 and 2 
that often occur in large water-borne outbreaks. Availability of clean drinking water and 
proper disposal of waste water would be effective control strategies. Genotypes 3 and 4 are 
mostly spread through contaminated food stuffs, such as the infamous French figatellu 
sausage made from uncooked pig liver.115,143 Thorough heating effectively kills the virus and 
prevents infection.144 Although ineffectively, HEV can also be transmitted via blood 
transfusion,145,146 suggesting that screening of donor blood may be warranted. In addition, 
vertical transmission of HEV has been reported,147 indicating that extra caution is required in 
pregnant women. 
1.2.4 Why do we need antiviral drugs against hepatitis E virus? 
1.2.4.1 Current standard of care 
Experience in hepatitis E treatment is limited and largely restricted to chronic infections. For 
transplant patients, the first consideration is lowering immunosuppressive therapy which 
clears the infection in over 30% of patients.133 RBV monotherapy was reported successful in 
most chronic hepatitis E patients.83,148–151 Anemia was the most frequent side effect and 
necessitated dose reductions in a number of cases. Patients were treated for 3 months or 
longer and ribavirin is contraindicated during pregnancy. Pegylated IFNα (PEG-IFNα) 
treatment is another option.152 Successful combination therapy of PEG-IFNα and RBV was 
reported for a chronically HEV-infected HIV-1 patient153 and RBV also substantially decreased 
Chapter 1: General introduction to hepatitis A virus and hepatitis E virus 
 
30 
 
HEV RNA levels in a case of severe acute hepatitis E.154 Nevertheless, there is an urgent need 
for efficacious and nontoxic treatments for HEV infections that can be used to contain 
outbreaks and that are safe in pregnant woman. 
1.2.4.2 Future therapy for hepatitis E 
For the reasons stated above, safe and effective treatments for hepatitis E are urgently 
required. In case of acute infections, antiviral drugs would be useful to shorten the period of 
illness and prevent progression to fulminant hepatic failure. Such application would require 
rapid diagnosis of hepatitis E (see also Section 1.2.2.3). Another possibility would be to use 
antivirals to halt viral spread during epidemics and outbreaks. The fact that these outbreaks 
occur rather often in refugee camps (e.g. 155,156) may represent an opportunity for clinical 
trials testing the prophylactic potential of HEV inhibitors if such studies would be 
appropriate from an ethical point-of-view. 
In pregnant women, such drugs could be life-saving for both mother and child, on the 
condition that they are devoid of teratogenic and significant adverse effects. Ideally, these 
women should be screened regularly with a rapid and sensitive HEV test and treated as soon 
as possible. This may be difficult to implement in developing countries where genotype 1 is 
endemic, so an approved HEV inhibitor should be sufficiently potent to arrest an established 
(fulminant) infection. Modulation of the hormonal system may be another interesting 
therapeutic option, although the development of such strategy would require more detailed 
insights into disease pathogenesis. 
For chronically infected patients, rapid clearance of HEV is required before irreversible 
progression to cirrhosis has occurred. Ideally, these drugs should be applicable in a diverse 
range of immunocompromised patients without overt toxicity. Since RBV treatment has a 
rather good efficacy in chronically HEV-infected patients, a combination regimen with 
another HEV-inhibitor could be envisaged (as is currently being explored for HCV: ribavirin + 
direct-acting antiviral(s), (e.g. 157,158). This may allow decreasing the ribavirin dosage, thus 
reducing and hopefully avoiding anemia and other side effects. In addition, we observed a 
slight synergistic effect in vitro for the combination of RBV and IFNα,159 suggesting that such 
a combination regimen may be worth considering in the clinical setting. Successful 
combination therapy has already been reported for a chronically HEV-infected HIV 
patient.153 
Developing antiviral drugs for the treatment of HEV infections will commercially not be as 
rewarding as for instance the development of HCV inhibitors.160 Therefore, it appears 
opportune to consider other strategies than the classical discovery-development of 
completely new chemical entities as well, for instance off-label use of drugs with robust anti-
HEV activity that are registered for unrelated indications when such molecules would be 
identified.  
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1.3 Thesis objectives 
From the information provided in this introduction, it will be clear that there is a need for 
potent and selective inhibitors of HAV and HEV replication. Since no convenient methods 
were available for antiviral drug testing against these viruses, the first objective was to 
develop such antiviral assays for HAV (chapter 2), the HEV-like CTV (chapter 3) and HEV 
(chapter 4). As described (section 1.2.4.1), the main treatment for chronic HEV infections is 
RBV monotherapy. This regimen is mostly effective, although treatment failure may occur. 
Consequently, the second objective of this thesis was to study the underlying mechanism of 
action for the antiviral effect of RBV in vitro (chapter 4) and the third objective to investigate 
the role of mutations in the HEV genome potentially associated with RBV treatment failure 
(chapter 5). Chapter 6 aims (fourth objective) to provide background and interpretation to a 
recently published paper on the potential aggravation of hepatitis E by mTOR-inhibitors. The 
last aim  (fifth objective) was the development of a convenient small animal model for 
hepatitis E. As a first step in this direction, the full genome sequence of rat HEV isolate LA-
B350 was determined (chapter 7). 
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Chapter 2: Rapid and convenient assays to assess potential 
inhibitory activity on in vitro hepatitis A virus replication 
 
This chapter has been published in the following paper: 
Debing Y, Kaplan GG, Neyts J, Jochmans D. 2013. Rapid and convenient assays to assess 
potential inhibitory activity on in vitro hepatitis A replication. Antiviral Res 98:325-31. 
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Three different antiviral assays were developed for the in vitro screening of inhibitors of HAV 
of which (i) a CPE reduction assay suitable for medium-to-high-throughput screening and (ii) 
two virus yield reduction assays (based on quantification of viral RNA) for genotypes IB and 
IIIA. The assays were validated for antiviral studies with IFNα and amantadine HCl, two 
known inhibitors of HAV replication. IFNα effectively inhibited HAV replication, whereas the 
activity of amantadine HCl appeared to be strain-dependent. Employing these assays, we 
assessed the effect of the known enterovirus inhibitors pleconaril, rupintrivir and enviroxime 
on HAV replication. Pleconaril exhibited some very moderate activity, the effect of rupintrivir 
proved to be strain-dependent. Enviroxime did not inhibit HAV replication, suggesting that 
PI4KIIIβ is not crucial in the HAV life cycle. 
2.1 Introduction 
HAV is an atypical member of the Picornaviridae and among the leading causes of enterically 
transmitted hepatitis worldwide (see also chapter 1).161 Infections are often asymptomatic, 
especially in children, but result occasionally in jaundice, fever, fatigue and malaise. It is 
estimated that about 1.5 million clinical cases of hepatitis A occur annually.161 Full recovery 
is the rule for most symptomatic HAV infections, although some patients display relapsing 
infection or fulminant hepatitis, especially the elderly. This results in mortality rates up to 
5.4% in those aged over 50.6 Superinfections with HAV in patients chronically infected with 
hepatitis B or C are believed to increase morbidity and mortality,7,8 although these findings 
are still subject of debate.10 HAV is transmitted through the feco-oral route and 
consequently, epidemics most often occur in regions with poor hygienic and sanitary 
conditions. Although efficacious vaccines are commercially available against the single HAV 
serotype, outbreaks are still reported rather frequently in developed countries.13,162 The 
current treatment is merely supportive: rest, adequate hydratation and proper nutritional 
balance are advised.163 For severe infections and for the purpose of containment of 
epidemics, but also to shorten the period of illness (several weeks), a safe and potent 
antiviral molecule would be much appreciated. A recent report warned for the potential 
emergence of new serotypes.18 Rapid intervention with an antiviral would be a useful tool in 
halting the spread of such vaccine-escape variants. A limited number of molecules has been 
reported to inhibit the in vitro replication of HAV. Antiviral activities have been described for 
amantadine, RBV, glycyrrhizin, pyrazofurin, amphotericin B, atropine and protamine by using 
various methodologies such as solid-phase radioimmunoassays, antigen stainings and RNA 
hybridization assays.29,164–167 Limited antiviral activity has been described for chlorpromazine 
and chloroquine.31 However, clinical use of these compounds is hampered by poor selectivity 
or toxic side effects. IFNα is active in vitro against HAV and has shown some effect in the 
treatment of severe HAV infections,168,169 but clinical use is associated with severe side 
effects. 
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Since the arrival of vaccines, research interest in HAV has decreased substantially.16 To the 
best of our knowledge, no cell-based screening assays against HAV have been reported in 
the last decade. Moreover, the antiviral assays that were reported earlier are labor-intensive 
and allow only to evaluate a small number of molecules. Here we report a CPE reduction 
assay amenable for high-throughput screening purposes. In addition, we present virus yield 
reduction assays (based on RT-qPCR) that can be used as a secondary assay to confirm and 
validate the activities of hits identified in the CPE-based assay. We employed these assays to 
assess the potential inhibitory activity of a small panel of known enterovirus inhibitors 
(pleconaril, rupintrivir and enviroxime) against HAV. 
2.2 Materials and methods 
2.2.1 Cells and viruses 
FRhK-4 cells (ATCC CRL-1688) and BS-C-1 cells (ATCC CCL-26) were grown in Dulbecco’s 
modified Eagle’s medium (DMEM, Gibco, Gent, Belgium) supplemented with 10% fetal 
bovine serum (FBS, Integro, Leuvenheim, the Netherlands). Huh7-A-I cells supporting stable 
HAV growth74 were grown in DMEM supplemented with 10% FBS and were subcultured 
twice a week at a 1:5 ratio. Huh7-A-I slow (Huh7-A-IS) cells were obtained by subculturing 
Huh7-A-I once a week (1:5 split ratio) for 20 passages in DMEM with 10% FBS and then for 
10 passages in minimal essential medium (MEM) rega 3 (Gibco) supplemented with 10% FBS, 
1% L-glutamine (Gibco) and 1% sodium bicarbonate (Gibco). All cell lines were grown in a 
humidified 5% CO2 incubator at 37°C. 
Cell culture-adapted cytopathic HAV strain HM175/18f (genotype IB, ATCC VR-1402)75 and 
HAV strain PA21 (genotype IIIA, ATCC VR-1357)69 were grown in BS-C-1 cells in DMEM with 
2% FBS at 35°C. Blasticidin resistance-conferring HAV8Y-Bsd virus74 was cultured in Huh7-A-I 
cells in DMEM with 10% FBS and blasticidin (Invitrogen, Carlsbad, CA, added 24 h post 
infection) at 2 µg/mL at 35°C. Virus was harvested by 3 freeze-thaw cycles followed by 
centrifugation at 1000g for 10 min at 4°C. Since a fungal contamination was reported for the 
PA21 strain by ATCC, the purchased stock was filtered through a 0.20 µm Millex filter 
(Millipore, Billerica, MA) and after infection cultured for 3 weeks in medium containing 
penicillin (100 U/mL, Gibco), streptomycin (100 µg/mL, Gibco) and nystatin (50 µg/mL, 
Sigma-Aldrich, St. Louis, MO) with weekly medium changes. Amphotericin B, although 
suggested by ATCC, was not used since a (limited) antiviral effect has been reported against 
HAV.165,166 All antiviral experiments were performed in a humidified 5% CO2 incubator. 
HM175/18f and HAV8Y-Bsd stocks were titrated by end-point dilution. For HM175/18f, 
FRhK-4 cells were seeded in 96-well plates (BD Falcon, Franklin Lakes, NJ) at 2 x 104 cells per 
well in 100 µL of DMEM supplemented with 2% FBS and incubated at 37°C. After 24 h, cells 
were confluent, medium was removed and 100 µL of a 1:10 virus dilution series in medium 
was added to each well. For HAV8Y-Bsd, Huh7-A-I cells were seeded at 5 x 103 cells per well 
in 100 µL of DMEM with 10% FBS and 100 µL of a 1:10 virus dilution series in medium was 
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added to each well immediately. After 24 h, blasticidin was added to each well to a final 
concentration of 2 µg/mL. Each dilution was analyzed in 6-fold for both strains. Plates were 
incubated at 35 °C for 7 days and subsequently scored by microscopy. The tissue culture 
infectious dose 50 (TCID50) corresponds to a viral dose sufficient to induce CPE (HM175/18f) 
or protect from blasticidin toxicity (HAV8Y-Bsd) in half of the cells in a tissue culture and was 
calculated by the method of Reed and Muench.170 Since the PA21 strain does not induce 
CPE, the number of RNA copies per mL as determined by RT-qPCR was used as a proxy for 
the infectious titer. 
2.2.2 Compounds 
IFNα 2b (Intron-A®) was purchased from Schering Plough (Kenilworth, NJ), diluted to 3 x 105 
international units (IU)/mL in phosphate-buffered saline (PBS, Lonza, Verviers, Belgium) 
supplemented with 10% glycerol and 0.1% bovine serum albumin, stored at -80°C and kept 
at 4°C after thawing. Amantadine HCl was from Sigma–Aldrich. RBV [1-(β-D-ribofuranosyl)-
1H-1,2,4-triazole-3-carboxamide (Virazole®)] was purchased from ICN Pharmaceuticals 
(Costa Mesa, CA). Pleconaril and enviroxime were synthesized as described before,171,172 
rupintrivir (AG-7088) was a gift from Pfizer (New York, NY). Compounds were dissolved in 
dimethylsulfoxide (DMSO) and stored at 4°C. 
2.2.3 CPE reduction assay 
FRhK-4 cells were seeded in 96-well plates at 2 x 104 cells per well in 100 µL of DMEM 
supplemented with 2% FBS and incubated at 37°C. After 24 h, cells were confluent, medium 
was removed and 100 µL of a 1:2 compound dilution series and 100 µL of HM175/18f 
dilution in medium, corresponding to a multiplicity of infection (m.o.i.) of 0.02, were added 
to each well. Virus controls (VC) and cell controls (CC) were included in each plate. Plates 
were incubated at 35°C. Seven days post infection, medium was removed and replaced with 
100 µL of a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium/phenazinemethosulphate (MTS/PMS, Promega, Leiden, the Netherlands) 
solution, as described.173 After an incubation period of 4 h at 37°C, the optical density (OD) 
at 498 nm was determined for each well. Antiviral activity was calculated with following 
formula: % antiviral activity = % CPE reduction = (ODvirus+compound–ODVC)/(ODCC–ODVC) ⁄ 100. 
Alternatively, quantification was done with the ATPlite luminescence assay system 
(PerkinElmer, Waltham, MA). The 50% effective concentration (EC50) is the concentration of 
compound that causes 50% protection of cells from virus-induced CPE and was calculated 
through logarithmic interpolation. For toxicity evaluation, plates were prepared in parallel 
with antiviral assays, but instead of virus dilution, 100 µL of plain medium was added. The 
50% cytotoxic concentration (CC50) is the concentration of compound that causes cell death 
in 50% of cultured cells and was estimated through logarithmic interpolation as well. Z’-
values were calculated as described.174 
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2.2.4 HM175/18 f virus yield assay 
FRhK-4 cells were seeded in 96-well plates at 2 x 104 cells per well in 100 µL of DMEM 
supplemented with 2% FBS and incubated at 37°C. After 24 h, cells were confluent. Medium 
was removed and replaced with 20 µL of medium containing compound and HM175/18f 
virus at an m.o.i. of 0.2. Plates were incubated at 35°C. The inoculum was removed after 1 h 
and cell layers were washed 3 times with 100 µL of PBS. To each well, 100 µL of compound 
dilution in medium was added. After incubation at 35°C for 3 days, the viral load in 100 µL of 
culture medium was determined by RT-qPCR. For evaluation of compound toxicity, 100 µL of 
MTS/PMS dilution was added to each well after medium removal, plates were incubated at 
37°C for 4 h and OD’s were determined as described. 
2.2.5 PA21 virus yield assay 
Huh7-A- IS cells were seeded in 96-well plates at 104 cells per well in 100 µL of MEM rega 3 
supplemented with 10% FBS, 1% L-glutamine and 1% sodium bicarbonate and incubated at 
37°C. After 24 h, medium was removed and replaced with 50 µL of medium containing 
compound and PA21 virus at 1.3 x 105 viral RNA copies per well. Plates were incubated at 
35°C. The inoculum was removed after 4 h and cell layers were washed twice with 100 µL of 
PBS. To each well, 100 µL of compound dilution in medium was added. After incubation at 
35°C for 7 days, the viral load in 100 µL of culture medium was determined by RT-qPCR. For 
toxicity evaluation, 100 µL of MTS/PMS dilution was added to each well after medium 
removal, plates were incubated at 37°C for 1 h and OD’s were determined as described. 
2.2.6 HAV8Y-Bsd virus yield assay 
Huh7-A-I cells were seeded in 96-well plates at 5 x 103 cells per well in 100 µL of DMEM 
supplemented with 10% FBS and incubated at 37°C. After 24 h, medium was removed and 
replaced with 100 µL of medium containing compound and HAV8Y-Bsd virus at an m.o.i. of 
0.002. Plates were incubated at 35°C. The inoculum was removed after 1 h and cell layers 
were washed 2 times with 100 µL of PBS. To each well, 100 µL of compound dilution in 
medium was added. After incubation at 35°C for 5 days, the viral load in 100 µL of culture 
medium was determined by RT-qPCR. For evaluation of compound toxicity, 100 µL of 
MTS/PMS dilution was added to each well after medium removal, plates were incubated at 
37°C for 1 h and OD’s were determined as described. 
2.2.7 RT-qPCR 
Viral RNA was extracted from culture medium with the NucleoSpin RNA virus kit (Macherey-
Nagel, Düren, Germany) according to the manufacturer’s instructions. Primers and probes 
for TaqMan-based quantification of HAV RNA were based on published sequences.33 As a 
forward primer 5’-GGCATTTAGGTTTTTCCTCATTCTTA-3’ was used for HM175/18f and HAV8Y-
Bsd and 5’-GGCATTTAGGTTTTTCCTCATCAATA-3’ for PA21, reverse primers were 
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5’-AATGTCTGCCAAAGACAGGATGT-3’ for HM175/18f and HAV8Y-Bsd and 
5’-CACATCTGCCAAAGACAGAATGT-3’ for PA21. Probes were labeled with 6-
carboxyfluorescein (FAM) at the 5’ end and with a minor groove binder (MGB) at the 3’ end 
(5’-6FAM-CAAGGTATTTTCCAGACTGTTGGGAGTGGTCT-MGBNFQ-3’ for HM175/18f and 
HAV8Y-Bsd, 5’-6FAM-CAAGGTATTTTCCAGACTGTTGGGAGTGGCCT-3’-MGBNFQ for PA21). 
Reactions were performed with One-Step qRT-PCR mix (Eurogentec, Seraing, Belgium) in a 
final volume of 25 µL containing 3 µM of each primer, 67 nM of probe and 5 µL of RNA 
sample. PCR was performed using the ABI 7500 Fast Real-Time PCR System (Applied 
Biosystems, Foster City, CA) under following conditions: 30 min at 48°C and 10 min at 95°C, 
followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Data were analyzed with ABI PRISM 
7500 SDS software (version 1.3.1, Applied Biosystems). For absolute quantification, standard 
curves were generated using 10-fold dilutions of template preparations of known 
concentrations. 
2.3 Results 
A CPE reduction assay was developed to allow the rapid, convenient and reproducible 
evaluation of the potential anti-HAV activity of compound libraries. The cell culture-adapted, 
cytopathic HM175/18f strain was used to this end since it induces a rapid and complete CPE 
in FRhK-4 cells.75 Initial optimization experiments indicated that infection at an m.o.i. of 0.02 
on confluent FRhK-4 cells with subsequent incubation for 7 days at 35°C results in sufficient 
CPE for detection with the MTS/PMS method. The Z’-value of the assay was calculated to be 
0.63. This calculation was based on 390 wells of both uninfected and infected cultures 
(collected from 3 independent experiments, figure 2.1). 
 
Figure 2.1 Assay quality as assessed by calculation of Z’ value. For both conditions, a total of 
390 values was obtained over 3 independent experiments. 
IFNα was used for validation of the antiviral assay (figure 2.2 A and C). An EC50 of 110 ± 70 
IU/mL was calculated and no cytotoxicity was detected at concentrations up to 3000 IU/mL. 
When CPE reduction was quantified by measuring intracellular ATP levels, an EC50 of 60 ± 20 
Chapter 2: Rapid and convenient assays to assess potential inhibitory activity on hepatitis A virus 
replication 
 
39 
 
IU/mL was calculated (figure 2.2 B and C). Dose response curves generated by both methods 
were comparable. Microscopic scoring confirmed these data obtained by the MTS/PMS and 
the ATP detection methods (figure 2.2 C and D). Amantadine HCl, a known inhibitor of HAV 
replication,175 resulted in complete inhibition of virus-induced CPE at a concentration of 125 
µM, as assessed by the MTS/PMS-method (figure 2.2 E) and corroborated by microscopical 
evaluation (figure 2.2 D). 
 
Figure 2.2 CPE reduction assay. Inhibition of CPE formation by HM175/18f and cell viability 
after IFNα treatment were assessed by MTS (A) and ATPlite (B) read-out. Results are similar 
for both methods and correspond to values obtained by microscopic scoring (C). HM175/18f 
causes extensive CPE after 7 days, which is efficiently inhibited by IFNα at 1500 and 375 
IU/mL and by amantadine HCl at 125 µM (D and E). Pleconaril exhibits moderate anti-HAV 
activity in the CPE reduction assay (F), no antiviral activity could be detected for rupintrivir or 
enviroxime (G and H). A–G: Results represent 7–10 measurements from at least 3 
independent experiments. H: 4–5 measurements, 2 independent experiments. Values 
represent mean ± standard deviation (SD). 
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The potential antiviral activity of 3 known inhibitors of in vitro enterovirus replication, i.e. 
pleconaril, rupintrivir (also known as AG7088) and enviroxime, was evaluated in the CPE 
reduction assay. Pleconaril exhibited moderate antiviral activity with a maximal inhibition of 
70 ± 11% at 25 µM and a calculated EC50 of 9 ± 3 µM (figure 2.2 F). Neither rupintrivir nor 
enviroxime inhibited virus-induced CPE formation (figure 2.2 G and H). 
To allow confirmation of the antiviral activity of hits identified in (future) antiviral screens in 
the CPE-based assay, we developed an RT-qPCR-based virus yield assay using the HM175/18f 
strain and FRhK-4 cells. From a pilot study, we observed that infection at an m.o.i. of 0.2 and 
an incubation period of 72 h at 35°C yielded sufficient levels of viral RNA for the efficient 
detection of potential antiviral effects. Using this assay, an EC50 of 20 ± 22 IU/mL was 
calculated for IFNα and 90 ± 23 µM for amantadine HCl (figure 2.3 A and B). The moderate 
antiviral effect of pleconaril as detected in the CPE assay was confirmed (EC50 of 7 ± 4 µM, 
figure 2.3 C). Neither rupintrivir nor enviroxime reduced viral RNA levels, thus confirming the 
results from the CPE reduction assay (figure 2.3 D and E). 
 
Figure 2.3 Virus yield assay for HAV HM175/18f with RT-qPCR over 72 h. Extensive antiviral 
activity was recorded for IFNα (A). To a more limited extent, amantadine HCl (B) and 
pleconaril (C) proved to be active as well. No selective antiviral effects were observed for 
rupintrivir (D) and enviroxime (E). A and B: 8 measurements, 3 independent experiments. C 
and D: 5 measurements, 3 independent experiments. E: 4 measurements, 2 independent 
experiments. Values represent mean ± SD. 
A second RNA virus yield assay was developed using the PA21 strain and Huh7-A-IS cells. This 
strain is only weakly adapted to cell culture,69 hence sufficiently high viral RNA titers were 
only reached at 7 days post infection. A critical point for this assay is the requirement for 
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10% FBS in the medium over the entire assay period, initial tests with 2% FBS (as is standard 
in most antiviral assays) revealed that Huh7-A-IS (but also regular Huh7-A-I) become 
apoptotic after 3–4 days of culturing, in particular when confluent (data not shown). Since 
Huh7-A-IS divide markedly slower than the parent Huh7-A-I, they are well suited for 
extended incubation. As shown, the PA21 strain in these cells is considerably more sensitive 
to IFNα than for instance the HM175/18f strain in FRhK-4 cells. In fact, complete inhibition of 
viral replication was noted over a wide concentration range (EC50 of 2 ± 3 IU/mL). The PA21 
virus in Huh7-A-IS was however less sensitive to amantadine HCl than HM175/18f on FRhK-4 
(EC50 of 230 ± 46 µM, figure 2.4 A and B). Pleconaril proved somewhat more toxic in Huh7-A-
IS than in FRhK-4 cells, but also exhibited antiviral activity (EC50 of 7 ± 3 µM, figure 2.4 C). In 
contrast to the HM175/18f, some activity of the 3C inhibitor rupintrivir was observed (EC50 
of 11 ± 4 µM, figure 2.4 D). These observed differences may possibly be explained by the use 
of the particular virus strains, the cellular background or a combination of both. Also in this 
assay enviroxime proved not effective (figure 2.4 E). 
 
Figure 2.4 Virus yield assay for HAV PA21 with RT-qPCR over 7 days. Extensive antiviral 
activity was found for IFNα (A). Amantadine HCl and pleconaril exhibit only small selectivity 
windows (B and C). Toxicity is more pronounced for pleconaril in Huh7-A-IS compared to 
FRhK-4 (Fig. 3C). Contrary to results for HM175/18f, rupintrivir displays an antiviral effect 
against PA21 (D). No selective inhibition was observed for enviroxime (E). A and B: 8 
measurements, 3 independent experiments. C and D: 5 measurements, 3 independent 
experiments. E: 4 measurements, 2 independent experiments. Values represent mean ± SD. 
  
Chapter 2: Rapid and convenient assays to assess potential inhibitory activity on hepatitis A virus 
replication 
 
42 
 
Finally the effect of the 5 molecules studied was assessed against an almost wt strain, 
HAV8Y-Bsd. Apart from the blasticidin resistance gene, it contains only one adaptive 
mutation in the 2B-coding region (A216V) that does not seem to affect virulence.74 Huh7-A- I 
cells allow stable growth of this almost wt virus. Treatment with IFNα resulted in complete 
inhibition over a large concentration range (figure 2.5 A), (EC50 of 0.5 ± 0.2 IU/mL). EC50’s 
obtained for amantadine HCl (170 ± 90 µM) and pleconaril (10 ± 10 µM) are in the same 
order of magnitude as those calculated in the above described assays (figure 2.5 B and C). 
Rupintrivir displayed a limited antiviral effect (EC50 of 51 ± 9 µM) while enviroxime did not 
inhibit HAV8Y-Bsd replication (figure 2.5 D and E). 
 
Figure 2.5 Virus yield assay for HAV8Y-Bsd with RT-qPCR over 5 days. Extensive antiviral 
activity was recorded for IFNα (A). To a more limited extent, amantadine HCl (B), pleconaril 
(C) and rupintrivir (D) proved to be active. No selective antiviral effect was observed for 
enviroxime (E). A-B: 8 measurements, 3 independent experiments. C-D: 5 measurements, 3 
independent experiments. E: 4 measurements, 2 independent experiments. Values represent 
mean ± SD. 
2.4 Discussion 
We established three antiviral assays to identify inhibitors of the HAV. The HM175/18f-
based CPE reduction assay is suitable for medium-to-high-throughput screening purposes. 
Two virus RNA yield assays were developed that allow to assess the potential antiviral 
activity against genotypes IB and IIIA. Since the latter assays are rather costly and labor-
intensive, they would be less suitable for large scale screening campaigns, but very useful for 
further confirmation of hits identified in the CPE reduction assay. The systems were 
validated for antiviral studies with IFNα and amantadine HCl, two known inhibitors of in vitro 
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HAV replication. Moreover, the potential antiviral effect of a selection of three enterovirus 
inhibitors, i.e. the capsid binder pleconaril, the 3Cpro inhibitor rupintrivir and the 3A/PI4KIIIβ-
targeting compound enviroxime, was assessed. The effect of pleconaril and rupintrivir 
appeared to be cell type and/or virus strain-specific. Enviroxime, a direct PI4KIIIβ inhibitor 
with broad spectrum anti-enterovirus activity,176 was devoid of any activity against HAV. In 
addition, results were confirmed with an almost wt HAV strain (HAV8YBsd). 
The HM175/18f strain is a highly passaged HAV strain and adapted to growth in African 
green monkey kidney cell lines such as BS-C-1 and FRhK-4. When compared to wt HM175, 44 
mutations were noted.75 Although the physiological relevance of this highly adapted strain 
could be questioned, the mutations concern <1% of the entire 7.5kb HAV genome, which is 
far less than for instance the 15% sequence divergence between different genotypes.177 
Another concern could be the use of the non-hepatic FRhK-4 cell line, while wt HAV mainly 
replicates in the liver. We propose therefore to assess the potential antiviral effect of hits 
from a screen using HM175/18f in the PA21 virus yield assay using the hepatocyte cell line 
Huh7-A-IS. The PA21 virus has only been passaged a limited number of times.69 A potential 
issue for the PA21 virus yield system is the limited dynamic range (Ct values of 27–28 were 
obtained in the infected cultures at 7 days post infection). This however is virtually inevitable 
for a slow growing virus such as HAV and is probably not a significant issue in the initial 
assessment of an antiviral effect. 
The systems described here have several strengths and advantages. First, at the inoculum 
used in the CPE reduction assay, multiple cycles of viral replication are required to obtain a 
sufficient level of CPE for MTS or ATPlite read-out. This allows for detection of antiviral 
activity at any step of the replication cycle and evaluation of cell viability after 7 days allows 
for a stringent assessment of potential cytotoxicity. Second, the RT-qPCR-based virus yield 
assay is highly sensitive. By using only a 3-day incubation for the HM175/18f strain, it is 
possible to study the antiviral effect in just one or a few replication cycles. A higher inoculum 
is required for such assays than in the CPE reduction assay to provide a sufficient dynamic 
range. On the other hand, the PA21 virus yield assay employs a limitedly adapted genotype 
IIIA virus in a hepatocyte cell line and thus offers a set of more physiological conditions. To 
our knowledge no cytopathic variants of HAV have been described other than those 
belonging to genotype IA or IB. Also, genotypes I and III are the most common genotypes 
isolated.178 Third, compared to the assays described in the late 1980’s – early 1990’s, our 
systems do not require radioactivity or evaluation by immunostaining and the CPE reduction 
assay can be employed in medium-to-high-throughput screening campaigns. The 
methodologies reported here are convenient, robust, reproducible and reliable. We also 
implemented an antiviral screening assay based on the blasticidin resistance-carrying strain 
HAV8Y-Bsd in Huh7-A-I cells.74 A negative selection assay with addition of blasticidin to 
culture medium 2 days post infection and MTS read-out after 7 days was successfully 
developed, but yielded several false positive hits in an antiviral screen (unpublished results). 
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This may be explained by a direct inhibition of the blasticidin S deaminase instead of 
blockage of viral replication. 
It has since long been established that HAV is susceptible to the antiviral activity of IFNα, 
both in vitro and in vivo.168,169 We here report EC50’s ranging from 0.5 to 110 IU/mL 
depending on the assay, which is in line with values reported by Crance and colleagues (<10 
to 90 IU/mL, m.o.i.-dependent).168 Differences between assays may be explained by 
differences in the cell types and virus genotypes employed, the extent of cell culture 
adaptation and the required time of incubation. The activity of amantadine has been 
reported as well with only a limited selectivity (EC50 = 58 µM).
165 Although initially thought to 
act as an inhibitor of intravesicular acidification and thus HAV uncoating, amantadine was 
later reported to block IRES-mediated translation of the viral genome.175 The results 
presented here corroborate the antiviral effect, even though the selectivity is very limited 
and the activity seems to be strain-dependent, as was found for different naturally occurring 
IRES’s as well.179 Pleconaril is an enterovirus inhibitor that targets receptor attachment and 
uncoating through binding into a hydrophobic pocket underneath the canyon present in the 
enterovirus capsid.180 The molecule is rather potent against most enteroviruses (with EC50’s 
in the range of 0.002–1 µM),181 here we report EC50’s between 7 and 10 µM for HAV. It is 
however rather surprising to observe activity of this molecule on HAV since the virion 
structure has no canyons comparable to those in enteroviruses.16 Further experiments are 
required to unravel by which mechanism pleconaril inhibits HAV. The lack of activity found 
for rupintrivir in HM175/18f experiments can be explained by limited sequence identity and 
significant variations in specificity-determining amino acid residues between HAV and 
enterovirus 3Cpro (see e.g. 182). These authors reported several broad-spectrum picornaviral 
3Cpro inhibitors that were inactive against a HAV subgenomic replicon.182 The fact that we 
observed some activity against PA21 and limited inhibition of HAV8Y-Bsd may be 
attributable to sequence differences between virus strains. The full PA21 sequence is 
currently not available through GenBank, sequencing of the PA21 3Cpro region and 
comparison with HM175/18f may shed light on these differences. HAV8Y-Bsd and 
HM175/18f differ in 3Cpro by one amino acid (Q101E),75 but this residue is not located near 
the catalytic side.183 Alternative explanations may be found in the different cell types or 
m.o.i.’s employed in the experiments. Although enviroxime selects for drug-resistance 
mutations in 3A, it functions by directly inhibiting PI4KIIIβ which is an essential host factor 
that is hijacked by enteroviruses for replication complex formation.176 Most picornaviral 3A 
proteins have a transmembrane region that targets to the ER from which the replication 
complexes are derived. Lack of activity of enviroxime against HAV is not unexpected since 
sequence homology between HAV and enteroviral 3A is very limited and more importantly, 
since HAV 3A is thought to target to the outer mitochondrial membrane, instead of to the 
ER, for derivation of replication complexes.50 The lack of activity for enviroxime and the 
mitochondrial origin of replication complexes suggest that PI4KIIIβ does not play a role in 
HAV replication. The assays described in the present report should allow for the first time 
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medium-to-high-throughput screening campaigns against HAV. Despite the fact that it would 
be important to have (a) drug(s) at hand for the treatment of severe and life-threatening 
cases of HAV infection, the investment cost to develop such drug from a new molecular 
entity may possibly seem too high in light of the potential market. Therefore screening of 
approved drug libraries may be an interesting option. Inhibitors (or combinations thereof) 
thus identified may be used off-label for the treatment of severe cases, to contain outbreaks 
and to combat the potential rise of vaccine-escape mutants (see also chapter 1, section 
1.1.3).18 Further studies may include validation of the observed results on primary human 
hepatocytes and evaluation of possible m.o.i.-effects. 
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Chapter 3: Cutthroat trout virus as a surrogate in vitro 
infection model for testing inhibitors of hepatitis E virus 
replication 
 
This chapter has been published in the following paper: 
Debing Y, Winton J, Neyts J, Dallmeier K. 2013. Cutthroat trout virus as a surrogate in vitro 
infection model for testing inhibitors of hepatitis E virus replication. Antiviral Res 100:98-
101. 
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HEV is one of the most important causes of acute hepatitis worldwide. Although most 
infections are self-limiting, mortality is particularly high in pregnant women. Chronic 
infections can occur in transplant and other immune-compromised patients. Successful 
treatment of chronic hepatitis E has been reported with RBV and PEG-IFNα, however severe 
side effects were observed. We employed the CTV, a non-pathogenic fish virus with 
remarkable similarities to HEV, as a potential surrogate for HEV and established an antiviral 
assay against this virus using the Chinook salmon embryo (CHSE-214) cell line. RBV and the 
respective trout IFN were found to efficiently inhibit CTV replication. Other known broad-
spectrum inhibitors of RNA virus replication such as the nucleoside analog 2’-C-
methylcytidine (2’CMC) resulted only in a moderate antiviral activity. In its natural fish host, 
CTV levels largely fluctuate during the reproductive cycle with the virus detected mainly 
during spawning. We wondered whether this aspect of CTV infection may serve as a 
surrogate model for the peculiar pathogenesis of HEV in pregnant women. To that end the 
effect of three sex steroids on in vitro CTV replication was evaluated. Whereas progesterone 
resulted in marked inhibition of virus replication, testosterone and 17β-estradiol stimulated 
viral growth. Our data thus indicate that CTV may serve as a surrogate model for HEV, both 
for antiviral experiments and studies on the replication biology of the Hepeviridae. 
3.1 Results and discussion 
Similar to HAV, HEV is one of the leading causes of acute hepatitis worldwide and is 
transmitted feco-orally.184 Four major genotypes are currently recognized; genotypes 1 and 
2 are restricted to humans so far, while viruses in genotypes 3 and 4 are known to be 
zoonotic agents with their major reservoir in domestic pigs.184 Even though overall mortality 
among humans is rather low, a recent analysis estimated that genotypes 1 and 2 cause an 
annual 70 000 deaths and 3000 stillbirths.114 Moreover, extraordinary mortality rates up to 
25% have been reported in pregnant women, particularly in those infected with genotype 
1.184–186 In industrialized countries, symptomatic hepatitis E is seen more frequently in older 
males.132,187,188 Treatment options are limited, although some experience has been gained in 
the management of chronic hepatitis E in immune-compromised and transplant patients.160 
Both PEG-IFNα and RBV are effective in most of these patients, but long treatment periods 
(up to three months) are required and severe adverse effects may occur.160 In addition, 
these regimens are contraindicated in pregnant women. Consequently more effective non-
toxic therapeutic options that can be used safely during pregnancy are required. 
Studying HEV infection/replication in vitro has long been hampered by the lack of 
susceptible cell culture models. In recent years, such efficient cell culture systems have been 
reported,189,190 but these have not been employed in antiviral studies yet. An alternative 
approach is to use a surrogate virus, as has been done for example with the duck HBV for 
HBV191 and bovine viral diarrhea virus (BVDV) for HCV.192 CTV, a small RNA virus of salmonid 
fish, was proposed as a potential surrogate for HEV.106 The CTV genome has a comparable 
size to the HEV genome and is organized in a similar way.106 Nucleotide sequence identity 
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was calculated to be around 40%, with 13–26% amino acid identity for the different ORFs.106 
Consequently, CTV has been proposed as a potential member of a second genus within the 
Hepeviridae family.97 No significant identity was found between the protease domains of 
CTV and HEV. However, when comparing the amino acid sequences of the helicase and RdRp 
of CTV and the 4 different HEV genotypes, 36–39% identity and 52–56% similarity was 
calculated (BLAST, see also 106). This argues for a considerably higher degree of evolutionary 
conservation than for instance the rather poor identity between the polymerase sequences 
of BVDV and HCV.193 These observations suggest that CTV could be an interesting model 
system for testing helicase inhibitors and nucleoside drugs. 
CTV was first isolated in 1988 from spawning adult trout and was subsequently detected in 
many salmonid populations in the western USA.106,194 CTV is considered avirulent in the 
salmonid species tested to date, but causes a diffuse CPE in CHSE-214 cells that is detectable 
only by visual inspection. We assessed whether this CPE can be quantified by conventional 
techniques amenable to antiviral assay development such as quantification of intracellular 
ATP or metabolism of tetrazolium dyes. However, the CTV-induced CPE proved not to be 
sufficiently extensive. As an alternative, a RT-qPCR-based virus yield assay was developed. To 
this end, Nunc 12.5 cm2 flasks (Thermo Scientific, Waltham, MA) were seeded with CHSE-214 
cells and grown in MEM (Gibco) supplemented with 10% FBS, 2 mM L-glutamine and 20 mM 
HEPES (Gibco) at 15°C in sealed flasks. After reaching confluency, cell layers were infected 
with CTV, based on a protocol described before:195 culture medium was removed and cell 
layers were incubated at room temperature with 1 mL of MEM with 2% FBS, HEPES (20 mM), 
penicillin (100 units/mL), streptomycin (100 µg/mL) and CTV at 1.5 x 107 RNA copies per mL 
(1988 Heenan lake isolate, GenBank accession number HQ731075). After 24 h, the inoculum 
was removed, cell layers were washed 4 times with 2 mL of PBS, 5 mL of fresh medium was 
added and cultures were incubated at 15°C. As shown in figure 3.1 A, CHSE-214 cells support 
robust replication of CTV with an overall growth of about 4 orders of magnitude within 2 
weeks. So after 14 days, viral RNA was extracted from 150 µL of culture medium (NucleoSpin 
RNA virus kit, Macherey–Nagel) and RT-qPCR of viral RNA was performed with One-Step 
qRT-PCR mix for SYBR Green I (Eurogentec) in a final volume of 25 µL containing 125 nM of 
each primer and 5 µL of RNA sample. The forward (5’-ACTGTTACACCCCATGTAGC-3’) and 
reverse (5’-GGACTTTACTAGCAGTGTGGA-3’) primers used in the assay were based on 
published sequences.106 RT-qPCR was performed using the ABI 7500 Fast Real-Time PCR 
System (Applied Biosystems) under following conditions: 30 min at 48°C and 10 min at 95°C, 
followed by 40 cycles of 15 s at 95°C, 30 s at 63°C and 30 s at 72°C. Data were analyzed with 
ABI PRISM 7500 SDS software (version 1.3.1, Applied Biosystems). For absolute 
quantification, standard curves were generated using 10-fold dilutions of the cloned target 
cDNA. 
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Figure 3.1 (A) Kinetics of CTV replication in CHSE-214 cells at 15 °C. (B) Reduction of CTV RNA 
levels after treatment with rainbow trout interferon 2 (rtIFN2), ribavirin (RBV) or 2’-C-
methylcytidine (2’CMC) as a percentage of untreated virus control (VC) or uninfected cell 
control (CC), respectively. Viral RNA copy numbers were normalized to cell counts from 
similarly treated yet uninfected toxicity controls. Values represent mean ± SD from 3 
independent experiments. ***p < 0.001, *p < 0.05, unpaired t-test. 
Since PEG-IFNα and RBV were found to result in some clinical efficacy in (chronically) HEV-
infected patients (for review see 160), the CTV virus yield assay was tested using recombinant 
rainbow trout IFN 2 (rtIFN2, a generous gift from Jun Zou, University of Aberdeen)196 and 
RBV (Virazole®; ICN pharmaceuticals). Viral titers were reduced to 15 ± 9% of virus control 
for rtIFN2 (20 ng/mL) and to 14 ± 12% and 4 ± 5% for RBV at 1 and 10 µM, respectively (p < 
0.001), without pronounced cytotoxicity (figure 3.1 B), although a slight cytostatic effect 
could be observed microscopically for RBV at 10 µM. Possible cytotoxicity was assessed in 
uninfected cultures treated in parallel and assayed for overall metabolic activity by the 
MTS/PMS method basically as described.173 Here, flasks with 2 mL of MTS/PMS medium 
were incubated at room temperature for 3h and the optical density (OD) at 498 nm was 
determined for 100 µL from each flask. 
Next, 2’CMC (Carbosynth, Compton, Berkshire, UK) and T705 (favipiravir; BOC Sciences, 
Shirley, NY), two known nucleoside analog inhibitors of RNA virus replication197,198 were 
tested for their ability to inhibit growth of CTV. While 2’CMC yielded only modest inhibition 
of virus replication at 25 and 100 µM (40 ± 30% of virus control, p < 0.05, and 30 ± 47%, p = 
0.06, respectively, figure 3.1 B), no antiviral activity was observed for T705 at 25 µM (110 ± 
61% of virus control, p = 0.79, n = 3). Of note, preliminary data from our lab indicate a similar 
pattern of activity against human HEV in a subgenomic replicon system in vitro.189,199 Taken 
together, these data suggest that CTV could be used as a surrogate for HEV in antiviral 
studies. 
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A potential drawback of the assay as described above is the rather long incubation period. 
However, in a pilot study to further adapt the virus to cell culture, the incubation period was 
shortened stepwise to select for fast-replicating strains. After just 9 passages, a comparable 
increase in viral titers could be reached in 7 days instead of 14 days for the wt strain (data 
not shown). With optimized culture conditions and plates, it should be feasible to further 
down-scale this assay to employ in small-scale screenings. Although the system does not 
offer a liver-like environment, it provides the possibility to screen for novel candidate 
inhibitors of HEV replication that are more potent and selective than IFN and RBV. Promising 
future approaches would be the construction of a selectable replicon expressing a reporter 
protein, thus allowing easy screening for replication inhibitors, and generation of antibodies 
for use in sandwich ELISA’s, immunofluorescence analyses or for inhibition of viral entry. 
In humans, mortality is increased dramatically in pregnant women infected with HEV.184–186 
This phenomenon is thought to be a consequence of hormonal changes during pregnancy 
and associated immunologic changes.200–202 Since CTV is detected only during spawning,106 it 
is possible that its replication is hormone-dependent as well. In order to gain a first insight 
into the possible underlying mechanisms, we studied whether there was a direct effect of 
sex steroids on CTV replication in CHSE-214 cells. Here progesterone was found to markedly 
decrease viral titers at 5 and 50 µM (40 ± 26% and 8 ± 5% of virus control, p < 0.05 and < 
0.001, respectively, figure 3.2 A), whereas testosterone and 17β-estradiol resulted in the 
stimulation of CTV replication, especially at 0.5 µM (500 ± 480% and 800 ± 600% of virus 
control, figure 3.2 B). Concentrations of 5 and 50 µM are considerably above physiological 
levels (e.g. 203). However, CHSE-214 cells are an embryo-derived continuous cell line204 that 
may be less sensitive to hormonal stimuli, as was observed for other piscine cell lines,205,206 
thus requiring increased concentrations of for instance progesterone to obtain notable 
differences in virus yields. In addition, the maturation-inducing steroid (MIS) in trout is not 
progesterone, but its 17,20β-dihydroxy-4-pregnen-3-one (17,20β-P) analog.207 Thus it may 
be possible that reasonably higher concentrations of the first are required to activate the 
cognate MIS receptor(s). On the other hand, the stimulation of CTV replication by 
testosterone and 17β-estradiol was most extensive at 0.5 µM, which is near physiological 
concentrations.203 Pronounced cytotoxicity was only observed for 17β-estradiol at 50 µM 
(figure 3.2 B). 
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Figure 3.2 Changes in CTV titers and cell viability after treatment with different 
concentrations of (A) progesterone, (B) testosterone or 17β-estradiol as a percentage of virus 
control (VC) or cell control (CC), respectively. Viral titers were normalized to cell counts as in 
figure 3.1. Values represent mean ± SD from at least 2 (cell viability) or 3 (viral RNA) 
independent experiments. ***p < 0.001, *p < 0.05, unpaired t-test. 
Trout vitellogenesis (i.e. production of yolk proteins from vitellogenin 
glycolipophosphoproteins) correlates with an increase in 17β-estradiol concentrations, while 
17,20β-P levels remain low.207,208 Subsequently, 17β-estradiol concentrations drop and 
17,20β-P concentrations rise during oocyte maturation and ovulation. Similarly, in male fish 
testosterone concentrations increase during spermatogenesis and decrease at spermiation 
which again is accompanied by a peak in 17,20β-P levels.209 CTV replication may be 
influenced directly by these changes in sex hormone concentrations. In conclusion, the 
notable coincidence between increased replication and shedding of CTV during spawning 
may not solely be due to hormonal modulation of the host immune system. Another 
plausible explanation may be growth stimulation of specific cell types by sex steroids210 that 
are more permissive for viral replication. This could not be studied in our system however. 
During pregnancy in humans, both progesterone and estradiol levels are elevated. In line 
with our findings, it was observed that high viral load, decreased expression of the 
progesterone receptor and presence of the PROGINS polymorphism in the progesterone 
receptor are associated with hepatitis E disease severity and poor outcome in pregnancy.202 
The PROGINS polymorphism is known to diminish response to progesterone.211 Thus, it may 
be hypothesized that decreased progesterone responsiveness allows for the more vigorous 
replication of HEV observed. In industrialized regions, symptomatic hepatitis E cases seem to 
occur more frequently in men over 50 years old.132,187,188 Testosterone levels gradually 
decrease in older males, which seems in agreement with our findings. Further research is 
required to study potential pro/antiviral effects of these hormones on HEV replication in 
vitro and in vivo and address the underlying mechanisms. However, the somewhat 
preliminary results obtained in our fish in vitro system suggest a possible evolutionary 
conserved mechanism in the natural history of both CTV and HEV. Moreover for HCV, 17β-
estradiol was found to be antiviral at a concentration of 0.4 µM in Huh7.5 cells, but no effect 
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was observed for progesterone (3 µM).212 This suggests that the replication of multiple 
hepatitis viruses may thus be directly influenced by sex hormone concentrations. 
In conclusion, CTV appears to be an interesting surrogate model for fundamental studies of 
HEV and for in vitro evaluation of potential antiviral drugs. As shown, the CTV replication 
cycle appears to be influenced by specific hormones, which may prove a useful starting point 
for future studies into the nature of the high mortality in pregnant women. In addition, 
CHSE-214 cells were determined to be female with a previously published RT-PCR method213 
(data not shown). Third, CTV is not pathogenic in humans (or in fish) and consequently it can 
be used in a BSL1 environment, thus avoiding safety concerns associated with HEV and other 
more closely related agents such as rat HEV and avian HEV. Finally, salmonid fish such as 
trout provide a readily available animal model for potential in vivo studies (e.g. 195). 
  
 
54 
 
 
  
 
55 
 
 
Chapter 4: Ribavirin inhibits in vitro hepatitis E virus 
replication through depletion of cellular GTP pools and is 
moderately synergistic with interferon alpha 
 
This chapter has been published in the following paper: 
Debing Y, Emerson SU, Wang Y, Pan Q, Balzarini J, Dallmeier K, Neyts J. 2014. Ribavirin 
inhibits in vitro hepatitis E virus replication through depletion of cellular GTP pools and is 
moderately synergistic with alpha interferon. Antimicrob Agents Chemother 58:267-73. 
Detailed protocols have been published on-line: 
Debing Y, Dallmeier K, Neyts J. 2014. Luminescence-based antiviral assay for hepatitis E 
virus. Bio-protocol.org [http://bio-protocol.org/e1196]. 
Debing Y, Dallmeier K, Neyts J. 2014. Infectious virus yield assay for hepatitis E virus. Bio-
protocol.org [http://bio-protocol.org/e1195]. 
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HEV is a common cause of acute hepatitis that results in high mortality in pregnant women 
and may establish chronic infections in immunocompromised patients. We demonstrate for 
the first time that IFNα and RBV inhibit in vitro HEV replication in both a subgenomic 
replicon and an infectious culture system based on a genotype 3 strain. IFNα showed a 
moderate but significant synergism with RBV. These findings corroborate the reported 
clinical effectiveness of both drugs. In addition, the antiviral activity of RBV against wt 
genotype 1, 2, and 3 strains was confirmed by immunofluorescence staining. Furthermore, 
the in vitro activity of RBV depends on depletion of intracellular GTP pools, which is evident 
from the facts that (i) other GTP-depleting agents (5-ethynyl-1-β-D-ribofuranosylimidazole-4-
carboxamide [EICAR] and mycophenolic acid [MPA]) inhibit viral replication, (ii) exogenously 
added guanosine reverses the antiviral effects, and (iii) a strong correlation (R2 = 0.9998) 
exists between the antiviral activity and GTP depletion of RBV and other GTP-depleting 
agents. 
4.1 Introduction 
HEV is a positive-sense, single-stranded RNA virus and is classified as the sole member of the 
Hepevirus genus in the Hepeviridae family.184,214 HEV is usually transmitted feco-orally and 
may cause self-limiting acute hepatitis. At least four genotypes are currently recognized: 
genotypes 1 and 2 seem to infect only humans and are endemic in developing regions, with 
an estimated 70 000 deaths annually,114 while genotypes 3 and 4 are zoonotic agents, with 
domestic pigs as their main reservoir.184,214 The latter two genotypes cause sporadic 
autochthonous infections in both developing and industrialized parts of the world, e.g., 
through consumption of undercooked pig meat.184,214 In addition, related viruses have been 
found in several animal species, including chickens (avian HEV),101 rats,103 rabbits,102 
ferrets,105 bats,104 and trout (CTV).106 
Infections with HEV are often severe in pregnant women infected with genotype 1, with up 
to 25% mortality.184,185 In addition, genotype 3 can cause chronic infections, particularly in 
immunocompromised individuals.160 The first consideration in treating chronic hepatitis E, 
especially in transplant patients, is lowering immunosuppressive therapy, which induces 
clearance in over 30% of cases.133 An additional course of PEG-IFNα for 3 months or longer 
proved successful in most cases described,215 but RBV monotherapy is probably the most 
frequently used option for chronic hepatitis E,160 and it also seems effective in severe acute 
infections.154,216 
Research on HEV has long been hampered by a lack of efficient cell culture models; however, 
in vitro cultures have been established in recent years.189,217 By employing a replicon, an 
infectious virus yield assay, and immunofluorescence staining, we investigated the antiviral 
activities of both IFNα and RBV against in vitro HEV replication. Depletion of intracellular GTP 
pools was found to be an important aspect of the mechanism of action of RBV. 
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4.2 Materials and methods 
4.2.1 In vitro transcription and capping 
HEV Kernow-C1 p6 (GenBank accession number JQ679013) and p6/luc-encoding RNAs were 
transcribed in vitro from MluI-digested plasmid DNA189 by use of the T7 RiboMAX Large Scale 
RNA production system (Promega, Madison, WI) and were capped with the ScriptCap m7G 
capping system (Cellscript, Madison, WI). To generate a transfection control for 
luminescence-based antiviral assays, the T7-IRES-FFLuc-YFsfRNA DNA fragment was PCR 
amplified from pT7-IRES-FFLuc-YFsfRNA with primers 5’-
CATATGTCGACTAATACGACTCACTATAGGGATCCGCCCCTCTCCC-3’ and 
5’-AGTGGTTTTGTGTTTGTCATCC-3’ and with Kapa HiFi HotStart ReadyMix master mix (Kapa 
Biosystems, Woburn, MA). The resulting fragment was in vitro transcribed. The IRES 
alleviates the need for capping, and the yellow fever virus-derived small flaviviral RNA 
(YFsfRNA) enhances the cellular stability of this firefly luciferase (FFLuc)-encoding RNA.218 
The generation of pT7-IRES-FFLuc-YFsfRNA will be described elsewhere. 
4.2.2 Cells and viruses 
Huh7 cells (a kind gift from Ralf Bartenschlager, University of Heidelberg, Heidelberg, 
Germany) and HepG2/C3A cells (a kind gift from Luc Verschaeve, Scientific Institute of Public 
Health, Brussels, Belgium) were cultured in DMEM supplemented with 10% FBS in a 
humidified 5% CO2 incubator at 37°C. 
To obtain infectious HEV stocks, HepG2/C3A cells seeded in a 6-well plate (BD Falcon, 
Franklin Lakes, NJ) were transfected with capped Kernow-C1 p6 RNA by use of DMRIE-C 
(Invitrogen) and were incubated at 35°C. Part of the culture medium was changed every 2 to 
3 days to ensure long-term cell survival, and culture medium was harvested from the original 
plate after 34 days of incubation. The obtained virus stock was propagated once more in 
HepG2/C3A cells, with weekly changing of half of the culture medium. Culture medium was 
harvested after 22 days. Since the Kernow-C1 p6 strain has been adapted to growth in 
HepG2/C3A cells,219 culturing of HEV p6 virus stocks in these cells resulted in higher-titer 
stocks than those obtained by culture in Huh7 cells (results not shown). 
HEV strain Sar 55 (GenBank accession number M80581), Akluj (accession number 
AF107909), LBPR-0379 (accession number JN564006), and Kernow-C1 (accession number 
HQ389543) inocula were obtained from human stool samples, while the human Mex 14 
strain (accession number M74506) was passaged once in a rhesus macaque. The work with 
human isolates was carried out under approved protocols of the Carolinas Medical Center 
(IRB-10-0709B) and the Royal Cornwall Hospital Trust (IRB-06Q2101/61), with the informed 
consent of the patients. The housing, maintenance, and care of the rhesus macaque met or 
exceeded all requirements for primate husbandry as specified in the Guide for the Care and 
Use of Laboratory Animals.220 
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4.2.3 Compounds 
IFNα 2a (Roferon-A®) was purchased from Roche Pharmaceuticals (Basel, Switzerland), 
diluted to 3 x 105 IU/mL in PBS (Lonza, Basel, Switzerland) supplemented with 10% glycerol 
and 0.1% bovine serum albumin, stored at -80°C, and kept at 4°C after thawing. RBV [1-(β-D-
ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide (Virazole®)] was purchased from ICN 
Pharmaceuticals. EICAR was a gift from Akira Matsuda (Hokkaido University), and MPA was 
purchased from Santa Cruz Biotechnology (Dallas, TX). Guanosine was from Sigma-Aldrich. 
Stock solutions of the compounds were made in DMSO and stored at 4°C. 
4.2.4 Luminescence-based antiviral assay 
Huh7 cells were seeded in 96-well plates (BD Falcon) at 7.5 x 103 cells per well in 100 µL of 
DMEM with 10% FBS and were incubated at 37°C. After 24 h, cell layers were washed once 
with DMEM and transfected with IRES-FFLuc-YFsfRNA and capped p6/luc RNA (100 ng per 
well [each]) by use of DMRIE-C reagent (0.2 µL per well) according to the manufacturer’s 
instructions. For CC wells, viral RNA was omitted. Plates were incubated at 37°C for 4 h. 
Afterwards, the transfection medium was removed, cell layers were washed twice with PBS 
(100 µL per well), and 100 µl of compound diluted in DMEM with 10% FBS was added to 
each well. For VC and CC wells, the compound was omitted. After incubation at 35°C for 3 
days, 20 µL of the culture medium was transferred to a white 96-well CulturPlate 
(PerkinElmer, Waltham, MA), and luminescence produced by the secreted Gaussia luciferase 
(GLuc) was determined after addition of 50 µL of diluted Renilla luciferase assay substrate 
(Promega). A pilot study indicated that incubation for 3 days was sufficient to obtain a 100-
fold increase in Gaussia-generated luminescence (data not shown), allowing for a fast and 
relatively sensitive readout. The remaining culture medium was removed, and 20 µL of 
passive lysis buffer (Promega) was added to each well. Next, the buffer with lysed cells was 
transferred to a white 96-well CulturPlate containing 100 µL of diluted FFLuc assay substrate 
(Promega) per well, and luminescence counts were obtained. GLuc luminescence values 
were normalized with the following formula: LucNormcompound = 
(GLucreplicon+compound‒GLucCC)/FFLucreplicon+compound. The percent antiviral activity was calculated 
as 100-(LucNormcompound/LucNormVC x 100). The EC50 was defined as the concentration of 
compound that caused a 50% reduction in the LucNorm signal compared to that of VC and 
was calculated through logarithmic interpolation. For toxicity evaluation, plates were 
prepared in parallel with antiviral assay mixtures, but the transfection step was omitted. 
After incubation for 3 days at 35°C, medium was removed and replaced with 100 µL of a 
MTS/PMS (Promega) solution, as described previously.173 After an incubation period of 2 h at 
37°C, the OD at 498 nm was determined for each well. The percent cell viability was 
calculated as follows: % viability = ODcompound/ODCC x 100. 
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For combination studies, a checkerboard with 3-fold dilutions of RBV and 4-fold dilutions of 
IFNα was used. Data were analyzed with the MacSynergy II template at the 95% confidence 
level.221 Volumes of synergy or antagonism below 25 µM2% are considered insignificant, 
while values between 25 and 50 µM2% are minor but significant. Volumes between 50 and 
100 µM2% indicate moderate synergy or antagonism.221–223 
4.2.5 Infectious virus yield assay 
Huh7 cells were seeded in 6-well plates at 5 x 105 cells per well in 2 mL of DMEM with 10% 
FBS, penicillin (100 units/mL), streptomycin (100 µg/mL), and amphotericin B (Fungizone) 
(2.5 µg/mL; Gibco) and were incubated at 37°C. After 24 h, culture medium was removed 
and cell layers were inoculated with infectious p6 virus at 2.1 x 105 RNA copies/mL in 1 mL of 
medium with DMSO (0.5%) or compound and then incubated at 35°C. After 5 h, the 
inoculum was removed, cell layers were washed 3 times with 2 mL of PBS, and 3 mL of 
medium with DMSO or compound was added to each well. After 1 h, a 150-µL sample was 
taken and stored at -80°C. Since HEV replication in vitro is rather poor, regular changing of 
the culture medium was required to allow cell survival over the full duration of the assay. 
Consequently, 750 µL was removed from each well every 2 to 3 days and stored at -80°C, 
and 1 mL of fresh medium with DMSO or compound was added. The viral loads in samples 
from 1 h, 12 or 13 days, and 20 days postinfection were determined by RT-qPCR. Statistical 
significance was calculated with the Mann-Whitney U test. On day 20 postinfection, all 
medium was removed from the plate, cell layers were washed with 2 mL of PBS, and 1 mL of 
MTS/PMS solution was added for evaluation of compound cytotoxicity. Cultures were 
incubated for 2 h at 37°C, and subsequently, the OD at 498 nm was determined for 100 µL 
from each well. Cell viability was expressed as a percentage of the DMSO control level. 
4.2.6 Immunofluorescence analysis and focus-forming assay 
HEVstrains Sar 55, Akluj, Mex 14, LBPR-0379, Kernow-C1, and Kernow-C1 p6 were inoculated 
onto HepG2/C3A cells seeded in 8-well Lab-Tek II CC2 chamber slides (Nunc). Cells in 
triplicate wells were incubated with medium with or without RBV at 200 µM. After 3 days, 
cells were fixed and stained for capsid protein as described before.219 Each well was 
manually scanned, and fluorescent cells or foci were counted. Cell viability of HepG2/C3A 
cells treated with RBV at 200 µM for 3 days was assessed with the MTS/PMS method. RBV 
was used at a higher concentration than that in Huh7 cells because HepG2 cells appear to 
require higher concentrations to induce intracellular GTP depletion (e.g., see reference 224). 
4.2.7 Quantification of intracellular GTP concentrations 
RBV, MPA, or EICAR was added to 1-day-old cultures of Huh7 cells in DMEM with 10% FBS in 
25-cm2 flasks. For RBV, concentrations of 2.5, 10, 25, and 100 µM were tested. For MPA and 
EICAR, concentrations of 0.1, 0.25, 1, and 2.5 µM were used. Untreated CC cultures were 
included as well. Flasks were incubated at 35°C for 3 days, and subsequently, cells were 
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detached using trypsin-EDTA solution (Gibco) and collected by centrifugation. Nucleotides 
were extracted from the cell pellet, and GTP levels were quantified by high-performance 
liquid chromatography as described previously.225 The 50% inhibitory concentration (IC50) 
was defined as the concentration of compound required to reduce the GTP levels to 50% of 
the levels in untreated control cultures. 
4.2.8 RT-qPCR 
Viral RNA was extracted from culture medium by use of a NucleoSpin RNA virus kit according 
to the manufacturer’s instructions. Primer and probe sequences for TaqMan-based 
quantification of HEV RNA were published previously.141 The forward primer 5’-
GGTGGTTTCTGGGGTGAC-3’ and the reverse primer 5’-AGGGGTTGGTTGGATGAA-3’ were 
used. The probe was labeled with FAM at the 5’ end and with a MGB at the 3’ end (5’-FAM-
TGATTCTCAGCCCTTCGC-MGBNFQ-3’).226 Reactions were performed with One-Step qRT-PCR 
mix (Eurogentec) in a final volume of 25 µL containing 250 nM of each primer, 100 nM of 
probe, and 5 µL of RNA sample. PCR was performed using an ABI 7500 Fast real-time PCR 
system (Applied Biosystems) under the following conditions: 30 min at 48°C and 10 min at 
95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Data were analyzed with ABI 
Prism 7500 SDS software (version 1.3.1; Applied Biosystems). For absolute quantification, 
standard curves were generated using 10-fold dilutions of the cloned target cDNA. 
4.3 Results 
We used a transient GLuc-expressing genotype 3 replicon (Kernow-C1 p6/luc)189 in Huh7 
hepatoma cells to assess the potential anti-HEV activity of RBV and IFNα, two drugs whose 
clinical efficacy has been reported in several case studies of HEV-infected patients.160,215 
Both RBV and IFNα efficiently inhibited HEV replication, with EC50’s of 3 ± 2 µM (0.7 ± 0.5 
µg/mL) and 1.3 ± 0.5 IU/mL, respectively (figure 4.1 A and B). The combination of both 
inhibitors resulted in a moderately synergistic antiviral effect, with a synergy volume of 72 
µM2% (figure 4.1 C). The combined antiviral activity was maximally 22% above the expected 
value (at about 4 IU/mL IFNα and 0.4 µM RBV). 
Next, the potential antiviral activity was assessed in Huh7 cells infected with the Kernow-C1 
p6 virus.189 Viral replication was quantified by means of RT-qPCR detection of viral RNA in 
the culture medium. Both IFNα and RBV resulted in significant reductions of viral titers at 12 
and 20 days postinfection (figure 4.1 D), without decreasing cell viability (RBV concentrations 
of up to 100 µM for 20 days) (figure 4.1 F). A dose-dependent inhibition of viral replication 
was observed with RBV, with a 4.1-log10 reduction in viral titer after 20 days at a 
concentration of 100 µM. Some differences in the antiviral potency of RBV observed 
between the replicon and virus yield assays, though limited, may be explained by the 
different setups (luminescence versus quantification of released viral RNA) and the 
respective time windows (3 versus 20 days) of the assays. 
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Figure 4.1 Inhibitory activities of IFNα and RBV against HEV replication. Huh7 cells were 
transfected with capped p6/luc RNA and treated with RBV (A) or IFNα (B) for 3 days. (C) 
Antiviral activities below or above those expected for RBV-IFNα combinations. (D) Antiviral 
activities were also assessed in an infectious virus yield assay with RT-qPCR detection of viral 
RNA. *, P < 0.05; **, P < 0.01. GE, genome equivalents. (E) RBV (200 µM) inhibited formation 
of foci in HepG2/C3A cells infected with strains Sar 55, Akluj, Mex 14, LBPR-0379, Kernow-C1, 
and Kernow-C1 p6. (F) Cell viability of Huh7 cells used in the infectious virus yield assay after 
20 days in the presence of IFNα or RBV, as assessed by the MTS/PMS method. (G) Cell 
viability of HepG2/C3A cells treated with RBV at 200 µM for 3 days was assessed by the same 
method. Values represent means ± SD for at least 3 independent experiments (A to D, F, and 
G) or 3 replicates (E). 
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Since RBV was reported to be effective in the treatment of acute genotype 1 infections,154,216 
the antiviral activity of RBV against genotypes 1 and 2 was assessed. To this end, HepG2/C3A 
cells were infected with wt isolate Sar 55, Akluj (both genotype 1), or Mex 14 (genotype 2) 
and stained for capsid protein. These strains do not spread in cell culture but are able to 
replicate intracellularly. RBV treatment (200 µM) reduced the number of fluorescent foci to 
almost zero (figure 4.1 E). Comparable results were obtained for the wt genotype 3 strains 
LBPR-0379 and Kernow-C1 and for the cell culture-adapted Kernow-C1 p6 strain. No 
cytotoxicity was observed for RBV at 200 µM for 3 days (figure 4.1 G). In addition, treatment 
of Sar 55 GLuc-containing replicon cells with RBV resulted in a pronounced reduction of viral 
replication, even when addition of RBV was delayed until 4 days posttransfection and activity 
was assessed at 15 days posttransfection (data not shown). 
One of the proposed mechanisms of action for the broad-spectrum antiviral activity of RBV is 
that inhibition of inosine 5’-monophosphate dehydrogenase (IMPDH) by RBV 5’-
monophosphate results in depletion of the intracellular GTP pools, thus impeding RNA virus 
replication.227,228 To determine whether GTP depletion is involved in inhibition of in vitro HEV 
replication, we assessed the antiviral activities of two known IMPDH inhibitors: MPA (an 
immunosuppressive agent) and EICAR, a 5-ethynylimidazole analogue of RBV.229,230 Marked 
inhibition of HEV replication was observed in the replicon assay, with EC50’s of 0.20 ± 0.04 
µM and 0.115 ± 0.007 µM for MPA and EICAR, respectively (figure 4.2 A and B). 
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Figure 4.2 Dependence of the antiviral activity of RBV on the depletion of intracellular GTP 
pools. MPA (A) and EICAR (B) are known inhibitors of IMPDH and are potent inhibitors of HEV 
replication in the replicon assay. Values represent means ± SD for at least 3 independent 
experiments. 
It has been shown for several viruses that are sensitive to RBV that replenishing of 
intracellular GTP pools through addition of exogenous guanosine restores virus 
replication.227,231 Concordantly, the anti-HEV activities of RBV, MPA, and EICAR were 
reversed following addition of guanosine to the cell culture medium (figure 4.3 A to C). Next, 
we quantified the intracellular GTP pools of Huh7 cells and the effects of different 
concentrations of the three compounds. Normal GTP concentrations were calculated to be 
around 350 µM, and RBV, MPA, and EICAR effectively depleted GTP pools, with IC50’s of 18 ± 
9 µM, 0.5 ± 0.1 µM, and 0.3 ± 0.2 µM, respectively. A strong correlation between both the 
IC50s for GTP depletion and the respective antiviral EC50’s was calculated (R
2 = 0.9998) (figure 
4.3 D). 
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Figure 4.3 Replenishing GTP pools salvages HEV replication. Addition of exogenous guanosine 
to the culture medium (40 µM) salvages HEV replication and abolishes the antiviral effects of 
RBV (A), MPA (B), and EICAR (C) in the replicon assay. (D) Relationship between the IC50’s for 
GTP depletion and EC50’s for inhibition of viral replication. Values represent means ± SD for at 
least 3 independent experiments. 
4.4 Discussion 
PEG-IFNα and RBV are the only drugs that are currently available to treat acute and chronic 
hepatitis E.160,215,216 Treatment duration is at least 12 weeks for chronic infections215 and a 
minimum of 3 weeks for acute infections154,216,232 (compare with the current standard of 
care for hepatitis C, i.e., PEG-IFNα plus RBV for up to 48 weeks, combined with a protease 
inhibitor for genotype 1 infections233). The scientific evidence for these hepatitis E 
treatments is limited to a number of case series and the in vitro activity against CTV, a HEV 
surrogate.199 None of these interventions or the superiority of one over the other has been 
validated in controlled trials yet. Here we demonstrate the antiviral activity of IFNα and RBV 
against HEV in vitro, thus providing additional evidence for the clinical use of these drugs. In 
addition, a moderate but statistically significant synergy was calculated for the combination 
of IFNα and RBV (figure 4.1 C). The clinical relevance of this observation is unclear, however, 
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since antiviral activity was maximally 22% above that expected. Nevertheless, since no 
antagonistic effects were observed, it might be an option to treat patients with a 
combination of IFNα and RBV, as is the case in the management of infections with hepatitis C 
virus (HCV). Lower doses of both drugs may possibly be sufficient in a combination regimen, 
thus reducing the frequency and severity of adverse effects. In fact, successful combination 
therapy has already been reported for a chronically HEV-infected HIV patient.153 
When the in vitro inhibitory concentrations of IFNα and RBV are compared to the serum 
concentrations typically obtained in (HCV-infected) patients, they seem to be in a roughly 
similar concentration range. For instance, mean PEG-IFNα serum concentrations of around 
80 IU/mL have been reported,234 which is considerably higher than the EC50 for inhibition of 
the HEV replicon, although this is lower than the 300 IU/mL that resulted in a 0.9-log10 
reduction in the virus yield assay. For RBV, serum concentrations between 8 and 13 µM have 
been reported,234,235 and hepatic accumulation of ribavirin has been claimed, with a steady-
state liver concentration of 250 µM.236 We calculated an EC50 of 3 µM for RBV and observed 
strong antiviral effects in the virus yield assays for concentrations above 10 µM. Although 
the relevance of such comparisons may be questionable, the fact that both IFNα and RBV are 
active in vitro is in agreement with the observed clinical efficacy of both in chronically HEV-
infected patients. 
In a recent study by Dong and colleagues, the HEV ORF3 protein was shown to inhibit IFNα 
signaling.237 In line with this finding, high concentrations of IFNα were required to reduce 
release of HEV RNA into the culture medium after infection (e.g., 50% reduction at 
concentrations as high as 1,000 units/mL). A similarly high concentration of 300 IU/mL was 
needed in our infectious HEV system to achieve reductions of viral RNA levels in the virus 
yield assay of 98% and 87% at 12 and 20 days postinfection, respectively (figure 4.1 D). In the 
replicon assay, on the other hand, we observed strong inhibition by IFNα at concentrations 
as low as 10 IU/mL (figure 4.1 B). Slight differences obtained in the infectious HEV system 
may be explained by the use of different cell lines (A549 versus Huh7) and virus isolates 
and/or the fact that the HEV infection was already established before the start of IFNα 
treatment in the study of Dong et al., while IFNα was included in the inoculum during initial 
infection in our virus yield system. However, the pronounced potency of IFNα against the 
subgenomic HEV replicon system can readily be explained by the lack of an interferon-
antagonizing activity in p6/luc, where expression of ORF3 is ablated by replacement with a 
reporter cassette, making the replicon especially susceptible to inhibition by IFNα. This is 
fully in line with the findings of Dong et al.237 
The data presented here indicate that depletion of cellular GTP pools is the predominant 
mechanism by which ribavirin inhibits in vitro HEV replication. It is unclear, however, to what 
extent hepatic GTP levels can be decreased by RBV in vivo.228 Other proposed mechanisms of 
action of RBV include immunomodulatory effects, modulation of IFN-stimulated gene 
expression, lethal mutagenesis forcing the virus into an error catastrophe, interference with 
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viral methyltransferase activity, direct inhibition of the viral polymerase, and inhibition of 
eIF4E interfering with cap-dependent translation.228 Although one or several of these 
mechanisms could be involved in the antiviral activity of RBV against HEV, the results 
presented here suggest that GTP depletion is an important mechanism contributing to its 
antiviral activity. 
Interestingly, the use of mycophenolate mofetil (MMP), a prodrug of MPA, for 
immunosuppressive therapy in transplant patients with chronic hepatitis E was significantly 
associated with HEV clearance.83 This observation is in accordance with the strong antiviral 
activity observed in our replicon assay (figure 4.2 A). However, it is questionable whether the 
antiviral effect outweighs the immunosuppresion that initially allowed HEV to establish a 
chronic infection. 
The replicon-based antiviral assay as described here is rather labor-intensive, but to our 
knowledge, it is the first reported system that allows testing of potential antiviral molecules 
targeting HEV replication. In addition, the results of the infectious virus yield indicate that it 
is feasible to study the impact of potential antiviral compounds on the replication of full-
length replication competent HEV. Although the isolation of the Kernow-C1 p6 strain was a 
major step forward, the replication kinetics are (still) rather slow, thus requiring long 
incubation times to obtain sufficiently high HEV titers for detection by RT-qPCR. Further 
adaptation to cell culture may be a possible solution; this strategy proved successful, for 
instance, for HAV and allowed for the development of relatively fast virus yield assays.238 
In conclusion, the observed in vitro antiviral activities provide additional support for the 
clinical use of both RBV and (PEG-)IFNα for the treatment of severe cases of hepatitis E. 
However, both therapies require long treatment periods and can have severe adverse 
effects. RBV dose reductions because of anemia have resulted in treatment failure and death 
in some cases.216 Consequently, the assays presented here may serve as a starting point for 
developing convenient systems for high-throughput screening. This should allow the 
development of more potent anti-HEV drugs with a better safety profile. Ideally, these drugs 
should be safe during pregnancy. Since HEV appears to be emerging and its impact on public 
health has been underestimated, it would be wise to invest in research toward such 
antivirals.
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Chapter 5: A mutation in the hepatitis E virus RNA 
polymerase promotes its replication and associates with 
failure of ribavirin treatment in recipients of organ 
transplants 
 
This chapter has been published (as a shorter version) in the following paper: 
Debing Y, Gisa A, Dallmeier K, Pischke S, Bremer B, Manns M, Wedemeyer H, Suneetha PV, 
Neyts J. 2014. A mutation in the hepatitis E virus RNA polymerase promotes its replication 
and associates with failure of ribavirin treatment in recipients of organ transplants. 
Gastroenterology 147:1008-11.   
Chapter 5: A mutation in the hepatitis E virus RNA polymerase promotes its replication and 
associates with failure of ribavirin treatment in recipients of organ transplants 
 
68 
 
We analyzed blood samples collected from 15 patients with chronic hepatitis E who were 
recipients of solid-organ transplants and were treated with RBV. All patients cleared the 
virus except for 2 non-responders; 1 patient died. A G1634R mutation in the viral 
polymerase was detected in the HEV RNA of the non-responders; this mutation did not 
provide the virus with resistance to RBV in vitro. However, the mutant form of a subgenomic 
replicon of genotype 3 HEV replicated more efficiently in vitro than HEV without this 
mutation, and the same was true for infectious virus, including in competition assays. Similar 
results were obtained for genotype 1 HEV. The G1634R mutation therefore appears to 
increase the replicative capacity of HEV in the human liver and hence reduce the efficacy of 
RBV. 
5.1 Introduction 
Hepatitis E is one of the most common forms of acute hepatitis worldwide.184 It is caused by 
infection with the HEV: a positive-sense single-stranded RNA virus classified in the genus 
Hepevirus in the Hepeviridae family (http://ictvonline.org/virusTaxonomy.asp) that is feco-
orally transmitted. Four different genotypes infecting humans have been described. 
Genotypes 1 and 2 are associated with water-borne outbreaks in developing countries and 
infect exclusively humans, whereas genotypes 3 and 4 are zoonotic; infections with these 
viruses occur worldwide and are often detected in commercial pig herds, but also in wild 
boar and deer.184,239,240 Consequently, human infections with the latter genotypes occur 
mainly through consumption of undercooked pig or deer meat.184,239 
Although infections with HEV can be asymptomatic, they often manifest as a typical acute 
hepatitis and usually resolve spontaneously. Concordantly, overall mortality is reported to 
be between 0.5-4%111,125 which is mainly due to the occurrence of fulminant hepatitis.184,239 
In contrast, pregnant women infected with genotype 1 are at high risk for fulminant 
hepatitis with potential obstetric complications and mortality rates as high as 10-25% (e.g. 
126,127). Another possible complication of hepatitis E is that genotype 3 (and possibly also 
genotype 4) infections may evolve to chronicity in immunocompromised patients, e.g. 
transplant or AIDS patients.129–131,241 In fact, several cases originally diagnosed as drug-
induced liver injury were afterwards found to be chronic hepatitis E.132 Such chronic 
infections may lead to cirrhosis, graft loss, liver decompensation and death over the course 
of just a few years.133 Factors possibly associated with the development of chronicity in HEV-
infected patients include tacrolimus therapy and low platelet count.133 Additionally, the risk 
of persistent infection is higher in heart and liver transplant recipients compared to kidney-
transplanted patients.242 
Treatment options for hepatitis E are currently very limited. For transplant patients with 
chronic HEV infections, lowering immunosuppresion leads to clearance of infection in 30% of 
cases.133 Alternatively, patients can be treated with an extended course of PEG-IFNα, but 
due to concerns of acute rejection, this is not recommended for heart or kidney transplant 
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patients. Therefore, RBV monotherapy (600-1000 mg/day for at least 3 to 5 months)216 is the 
treatment-of-choice for most patients.150,215 Both PEG-IFNα and RBV were found to be 
successful in the majority of reported cases215,216 and their inhibitory effects on HEV 
replication have been confirmed in vitro.159 However, both PEG-IFNα and RBV results in 
adverse effects and treatment failure has been observed for RBV monotherapy, often due to 
dose reductions because of severe anemia.216 
5.2 Materials and methods 
5.2.1 Study subjects 
All patients were recruited at Hannover Medical School between 2008 and 2014. Serum 
samples were collected from 15 solid organ-transplanted patients who developed chronic 
hepatitis E and received RBV treatment. All patients were infected with genotype 3 HEV. 
Serum samples were collected before (I), during (II) and after RBV treatment (III). At least 
one serum sample from each time point (I-III) was used for further studies. Written informed 
consent was obtained from each patient included in this study. The study protocol 
conformed to the ethical guidelines of the Institutional Review Committee. 
RBV (Rebetol® or Copegus®) was administered orally twice daily with an initial daily dose of 
600-1000 mg, depending on the patient’s hemoglobin level and comorbidities.216 Dose 
reductions were performed if hemoglobin levels declined and/or patients developed 
symptoms associated with anemia. At each visit, aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), γ-glutamyltranspeptidase (γGT) as well as HEV serology and HEV 
RNA viremia were determined. Anti-HEV status was determined using Wantai HEV IgG 
(Beijing, China). HEV RNA from serum was quantified by one-step RT-qPCR as described.141 
All patients cleared HEV RNA by the end of treatment, except for 2 chronically infected 
transplant recipients. 
5.2.2 Extraction and sequencing of HEV RNA from serum samples 
Total RNA was extracted from 200 µL of serum or EDTA-plasma using Cobas AmpliPrep total 
nucleic acid isolation kit (Roche, Basel, Switzerland). Total RNA concentration was measured 
using the NanoVue Plus spectrophotometer (GE Healthcare Life Sciences, Little Chalfont, 
UK). cDNA was synthesized from 4 to 8 μL of purified total RNA using the SuperScript III first-
strand synthesis system (Life Technologies, Carlsbad, CA) with the external reverse primer 
from each set (set1-4 A2 (ex)) at a final concentration of 2 µM (see table 5.1). A touchdown 
nested PCR with 4 sets of specific external and internal primer pairs listed in table 5.1 was 
used to amplify the coding regions of the HEV genome. The first PCR round was carried out 
with TaKaRa Ex Taq Hot Start Version (Dalian, China) using 8 μL of synthesized cDNA and an 
external primer pair at a final concentration of 1 µM each in a 50 μL reaction with 18 cycles 
of 30 s at 94°C, 45 s at 62°C with a reduction of 0.5°C/cycle and 1 min/kb at 72°C, followed 
by 14 cycles of 30 s at 94°C, 45 s at 53°C and 1 min/kb at 72°C. A final extension of 10 min at 
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72°C followed the final cycle. The second PCR round was carried out using internal primer 
pairs and 5 μL of the first-round PCR product with identical amplification parameters to the 
first round. The resulting amplicons were separated by agarose gel electrophoresis and 
purified using Qiaquick gel extraction kit (Qiagen, Hilden, Germany) and concentrations were 
measured using NanoVue Plus spectrophotometer. 
5.2.3 Sanger sequencing and analysis of HEV coding regions 
The purified PCR products were sequenced commercially (GATC Biotech, Konstanz, 
Germany) in both forward and reverse directions using the internal primer pairs from set 1-4 
(see table 5.1) on an automatic DNA sequencer (Sanger ABI 3730xl). To identify nucleotide 
and amino acid variations between different time points (before, during and after 
treatment) the nucleotide sequences from all sets were assembled using Sequencher 4.9 
software by Gene Codes (Ann Arbor, MI). 
5.2.4 Cells, viruses and replicons 
Huh7 cells and HepG2/C3A cells were cultured in DMEM supplemented with 10% FBS 
(Gibco) in a humidified 5% CO2 incubator at 37°C. Genotype 3 full-length and reporter 
replicon viral RNA was derived from plasmids encoding Kernow-C1 p6 (GenBank accession 
number JQ679013) and Kernow-C1 p6/luc HEV strains respectively.189 Genotype 1 replicon 
RNA was derived from Sar55/S17/luc-encoding plasmid.243 Both were kind gifts from 
Suzanne U. Emerson (NIAID, NIH, Bethesda, MD). Amino acid numbering is according to NCBI 
reference sequence NP_056779. 
5.2.5 Site-directed mutagenesis and plasmid preparation 
Mutations were introduced by PCR amplification of overlapping fragments with specifically 
mutated primers. To introduce the 1634R mutation into the Kernow-C1 p6/luc replicon, PCR 
amplifications were performed with primer pairs KC1p6-AflII-5’f + KC1p6-1634Rr and KC1p6-
1634Rf + KC1p6/luc-NruI-3’r (see table 5.1 for primer sequences). Consequently both 
fragments were combined in a fusion PCR with primers KC1p6-AflII-5’f and KC1p6/luc-NruI-
3’r. PCRs were performed with KAPA HiFi HotStart ReadyMix PCR kit. The resulting fragment 
was digested with AflII, phosphorylated and ligated into AflII- and NruI-digested Kernow-C1 
p6/luc plasmid. Similarly, primer pairs KC1p6-AflII-5’f + KC1p6-1634Kr and KC1p6-1634Kf + 
KC1p6/luc-NruI-3’r were used to introduce the 1634K mutation. To mutate the full-length 
Kernow-C1 p6 plasmid, PCRs were performed with the same primer sets except KC1p6-PmlI-
3’r was used as the ultimate 3’-end primer. The resulting fusion fragment was digested with 
AflII, phosphorylated and ligated into AflII- and PmlI-digested Kernow-C1 p6 vector. 
To mutate the genotype 1 Sar55/S17/luc construct (wt: K1634), PCRs were performed with 
primer pairs SarLuc-SfiI-5’f + SarLuc-1634Gr and SarLuc-1634Gf + SarLuc-NheI-3’r (1634G), 
SarLuc-SfiI-5’f + SarLuc-1634Rr and SarLuc-1634Rf + SarLuc-NheI-3’r (1634R), SarLuc-SfiI-5’f + 
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SarLuc-1634Er and SarLuc-1634Ef + SarLuc-NheI-3’r (1634E), SarLuc-SfiI-5’f + SarLuc-1634Qr 
and SarLuc-1634Qf + SarLuc-NheI-3’r (1634Q), SarLuc-SfiI-5’f + SarLuc-1346Gr and SarLuc-
1346Gf + SarLuc-NheI-3’r (1346G), SarLuc-SfiI-5’f + SarLuc-1498Pr and SarLuc-1498Pf + 
SarLuc-NheI-3’r (1498P), SarLuc-SfiI-5’f + SarLuc-1346Gr and SarLuc-1346Gf + SarLuc-1498Pr 
and SarLuc-1498Pf + SarLuc-NheI-3’r (1346G + 1498P). Fragments were combined in fusion 
PCRs with primers SarLuc-SfiI-5’f and SarLuc-NheI-3’r and digested with NheI and SfiI. The 
resulting fragments were ligated into NheI- and SfiI-digested Sar55/S17/luc vector. E. coli 
Top10 cells (Life Technologies) were transformed with ligated plasmids. Kernow-C1-related 
constructs were cultured in 500 mL of Super Broth with ampicillin and maxiprepped (Plasmid 
maxi kit, Qiagen). Sar55-related plasmids were cultured in 100 mL of LB medium with 
ampicillin and midiprepped (NucleoBond Xtra midi kit, Macherey-Nagel). The cloned regions 
in each of the constructs were sequenced to ensure that no additional mutations had been 
introduced. 
5.2.6 In vitro transcription and capping 
Viral RNA was in vitro transcribed from MluI- (Kernow-related) or BglII- (Sar55-related) 
linearized plasmid DNA with the RiboMAX Large Scale RNA Production System-T7 and 
capped with the ScriptCap m7G capping system. A FFLuc-based transfection control was 
generated as described.159 Nucleic acid concentrations were determined by spectroscopy 
(Nanodrop ND-1000, Thermo Fischer Scientific). 
5.2.7 Antiviral assay 
Luminescence-based antiviral assays were performed essentially as described.159 RBV [1-(β-
D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide (Virazole®)] was purchased from ICN 
Pharmaceuticals. A stock solution was prepared in DMSO and stored at 4°C. 
5.2.8 Replicon assays 
Huh7 and HepG2/C3A cells were seeded into 6-well plates at 2 x 105 cells per well and 
transfected with capped RNA transcripts (1 µg per well) 24 h later using Lipofectin (Life 
Technologies) according to the manufacturer’s instructions. After 72 h of incubation at 35°C, 
GLuc activity was measured in 20 µL of culture medium with the Renilla luciferase assay 
system (Promega). 
For replicon competition assays, Huh7 and HepG2/C3A cells were seeded into 12-well plates 
at 8 x 104 cells per well. RNA was produced for each wt and mutant Kernow-C1 p6/luc 
replicon and 2 types of uncapped RNA were mixed in 10:1, 1:1 and 1:10 ratios. Mixtures 
were capped and 0.4 µg per well was transfected into cells 24 h after seeding with 
Lipofectin. After 72 h of incubation at 35°C, GLuc activity was determined. 
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5.2.9 Full-length HEV replication kinetics and competition assays 
To determine the growth kinetics of wt and mutant full-length HEV (G1634, 1634R and 
1634K), Huh7 and HepG2/C3A cells were seeded into 6-well plates at 2 x 105 cells per well 
and transfected with capped RNA transcripts for Kernow-C1 p6 wt or mutants (1 µg per 
well). DMSO (0.125%) or RBV at 10 or 25 µM were included in the culture medium. One mL 
of the medium was removed every 2-3 days, stored at -80°C until RNA extraction and 1mL of 
fresh medium (with DMSO or RBV) was added to each well. After 20 days, cell layers were 
lysed and intracellular RNA was extracted with the Qiagen RNeasy kit. To extract viral RNA 
from culture medium, RNase A (Promega) was added to 100 µL of thawed medium to a final 
concentration of 200 ng/mL and incubated at room temperature for 5’ to reduce the amount 
of residual in vitro transcripts from RNA transfection. Viral RNA was extracted with the 
NucleoSpin RNA virus kit and quantified by RT-qPCR. 
For infectious virus competition assays, Huh7 and HepG2/C3A cells were seeded into 6-well 
plates at 2 x 105 cells per well. RNA was produced for Kernow-C1 p6 wt and 1634R mutant 
and was mixed in 10:1, 1:1 and 1:10 ratios. Mixtures were capped and transfected with 
Lipofectin into cells 24 h after seeding. One mL of the medium was removed every 2-3 days, 
stored at -80°C until RNA extraction and 1 mL of fresh medium was added to each well. 
RNase treatment and RNA extractions were performed as described above. RNA extracts 
were analyzed by allele-specific multiplex RT-qPCR. Input RNA mixtures and RNA extracts 
from cell lysates were subjected to RT-PCR with primers KC1p6-AflII-5’f and KC1p6-PmlI-3’r 
(Onestep RT-PCR kit, Qiagen) and subsequent Sanger sequencing with primer KC1p6-AflII-5’f 
(BigDye Terminator v3.1 cycle sequencing kit, Life Technologies) for semi-quantitative 
assessment of the G1634 : 1634R ratio. For calculation of relative fitness gains, the fitness of 
G1634 and 1634R strains is considered 1 and 1+s respectively with s being the relative 
fitness gain. s is calculated as described.244 
5.2.10  RT-qPCR 
Quantification of total HEV RNA was performed essentially as described with primers HEVqf 
and HEVqr and probe HEVqp.159 For absolute quantification of intracellular viral RNA, copy 
numbers were normalized to total RNA per sample as determined by spectroscopy. 
Allele-specific multiplex RT-qPCR was performed with primers KC1p6-asqf and KC1p6-asqr. 
As probes, KC1p6-asqpG and KC1p6-asqpR were used (see table 5.1). Reactions were 
performed with One-Step qRT-PCR mix (Eurogentec) in a final volume of 25 µL containing 
375 nM of each primer, 125 nM of each probe and 5 µL of RNA sample using the ABI 7500 
Fast Real-Time PCR System (Applied Biosystems) under following conditions: 30 min at 48°C 
and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Data were 
analyzed with ABI PRISM 7500 SDS software (version 1.3.1, Applied Biosystems). For 
absolute quantification, standard curves were generated using 10-fold dilutions of the 
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cloned target cDNA. Concentrations of DNA standards were calculated by spectroscopy (for 
regular RT-qPCR) or RT-qPCR (for allele-specific multiplex RT-qPCR). In order to validate the 
allele-specific multiplex RT-qPCR, mixtures of G1634 and 1634R RNA were made in known 
ratios (0, 20, 40, 60, 80 and 100% wt) and analyzed. Results show a strong correlation 
between expected and experimentally obtained fractions of wt (figure 5.1, R² = 0.9895, n = 
3). 
 
Figure 5.1 Allele-specific RT-qPCR validation. Mixtures of G1634 and 1634K in known ratios 
were analyzed by allele-specific RT-qPCR and results plotted as calculated percentage G1634 
(% G) versus theoretical % G. A strong correlation was found between both, validating this 
method for precise quantification of the ratio wt G1634 to 1634R (n = 3). 
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5.2.11  Primers and probes 
 
Primers for analysis of clinical samples 
Set Primer  Sequence 
1 Set1-S1 (ex) 5’-AGGCTCCTGGCATTACTACTG-3’ 
Set1-S2 (in) 5’-GCCTTGGCGAATGCTGTG-3’ 
Set1-A1 (in) 5’-GGCCGGGGATGTARTCACG-3’ 
Set1-A2 (ex) 5’-CGGCACTGRGCATARAACTG-3’ 
2 Set2-S1 (ex) 5’-ATGACATACCTYCGTGGYATTAG-3’ 
Set2-S2 (in) 5’-GTYGCYAATGAGGGKTGGAA-3’ 
Set2-A1 (in) 5’-TTGTGGTCTCTGTRAARGTRGCRCCCT-3’ 
Set2-A2 (ex) 5’-CRGCCGTRGCTATAATTGTRGTCT-3’ 
3 Set3-S1 (ex) 5’-GYTTTGCGGCCTTYACACCYCAYAC-3’ 
Set3-S2 (in) 5’-CGYCGTGTTGTKATTGAYGAGGC-3’ 
Set3-A1 (in) 5’-GRCCRGCAAAHCGCACYACAT-3’ 
Set3-A2 (ex) 5’-AACACARACCTGCGCRACATTCGT-3’ 
4 Set4-S1 (ex) 5’-CCTGGYACCCTYCTYTGGAAYAC-3’ 
Set4-S2 (in) 5’-TGGGYTGTATGCYGGTGTGGTRGT-3’ 
Set4-A1 (in) 5’-CAGCCGACGAAATCAATTCTG-3’ 
Set4-A2 (ex) 5’-CCCTTATCCTGCTGYGCATT-3’ 
Primers for mutagenesis and in vitro studies 
Primer name Sequence 
KC1p6-AflII-5’f 5’-TGATCACTTAAGGGTTTCTGGAAGAAGC-3’ 
KC1p6-1634Rr 5’-TCAACCTTCGAAGGAAATCACAAACAG-3’ 
KC1p6-1634Kr 5’-TCAACTTTCGAAGGAAATCACAAACAG-3’ 
KC1p6-1634Rf 5’-CTGTTTGTGATTTCCTTCGAAGGTTGACGAACG-3’ 
KC1p6-1634Kf 5’-CTGTTTGTGATTTCCTTCGAAAGTTGACGAACG-3’ 
KC1p6/luc-NruI-3’r 5’-CGAAGTTGCTGGCCACGGCCAC-3’ 
KC1p6-PmlI-3’r 5’-GTGAATCAACATCAGGTACAGGGGCTG-3’ 
SarLuc-SfiI-5’f 5’-AGATCTGGCCGTTATGGCCGCCGCACAAAG-3’ 
SarLuc-1634Gr 5’-TGAGCCCGCGGAGAAAATCACTCACAG-3’ 
SarLuc-1634Rr 5’-TGAGCCTGCGGAGAAAATCACTCACAG-3’ 
SarLuc-1634Er 5’-TGAGCTCGCGGAGAAAATCACTCACAG-3’ 
SarLuc-1634Qr 5’-TGAGCTGGCGGAGAAAATCACTCACAG-3’ 
SarLuc-1634Gf 5’-CTGTGAGTGATTTTCTCCGCGGGCTCACGAATG-3’ 
SarLuc-1634Rf 5’-CTGTGAGTGATTTTCTCCGCAGGCTCACGAATG-3’ 
SarLuc-1634Ef 5’-CTGTGAGTGATTTTCTCCGCGAGCTCACGAATG-3’ 
SarLuc-1634Qf 5’-CTGTGAGTGATTTTCTCCGCCAGCTCACGAATG-3’ 
SarLuc-1346Gr 5’-GCTCGTACAATTCCCCGGTTGTAACC-3’ 
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SarLuc-1346Gf 5’-GGTTACAACCGGGGAATTGTACGAGC-3’ 
SarLuc-1498Pr 5’-GCAGAATCCACGCAGGCCTTATAAGGTGG-3’ 
SarLuc-1498Pf 5’-CCACCTTATAAGGCCTGCGTGGATTCTGC-3’ 
SarLuc-NheI-3’r 5’-CAAGCAATGCTAGCACAGAGTGG-3’ 
HEVqf 5’-GGTGGTTTCTGGGGTGAC-3’ 
HEVqr 5’-AGGGGTTGGTTGGATGAA-3’ 
HEVqp 5’-6FAM-TGATTCTCAGCCCTTCGC-MGBNFQ-3’            (from Life 
Technologies) 
KC1p6-asqf 5’-TGCTGAGCAGCTACGTC-3’ 
KC1p6-asqr 5’-GGGCTAACTCCATAGACACG-3’ 
KC1p6-asqpG 5’-6FAM-TCCTTCGAG-ZEN-GGTTGACGA-IBFQ-3’ 
KC1p6-asqpR 5’-HEX-TCCTTCGAA-ZEN-GGTTGACGAA-IBFQ-3’ 
Table 5.1 Primers and probes used in this chapter. Restriction sites (or partial restriction 
sites) are underlined and mutated codons are in bold-type. All primers for quantification and 
analysis of clinical samples were purchased at Eurofins MWG Operon (Germany), while 
primers and probes for in vitro studies were purchased at Integrated DNA Technologies 
(Coralville, IA), unless otherwise indicated. K=G/T/U, M=A/C, R=A/G, S=C/G, W=A/T, Y=C/T/U, 
N=A/T/G/C, H=A/T/C, V=A/G/C, D=A/T/G. HEX, hexachlorofluorescein; IBFQ, Iowa black 
fluorescent quencher; MGBNFQ, minor groove-binding non-fluorescent quencher; ZEN, 
internal quencher. 
5.2.12  Statistical analysis 
Results for all experiments are derived from at least 3 independent experiments and were 
analyzed by two-tailed Student t test. 
5.3 Results 
5.3.1 Two cases of RBV treatment failure 
We report on 15 solid-organ-transplant patients with chronic hepatitis E (11 with genotype 
3c, 3 genotype 3f and 1 genotype 3e). RBV treatment was successful in all but 2 patients 
(both genotype 3c) who failed to clear the virus (13%, which is comparable to other studies 
reporting failure rates of 15-18%).150,216 The first patient was a male heart/kidney-recipient 
who was treated for 9 months and showed an initial decrease in viral RNA load upon 
initiation of RBV treatment but never became HEV RNA negative (i.e. below 1000 copies/mL, 
figure 5.1 A). Nevertheless, after 4 months of RBV therapy, HEV RNA loads increased again to 
baseline levels (even before a transient dose reduction because of anemia) and persisted 
over time. The patient died of hepatic decompensation as described previously.83 The 
second patient is a female lung/kidney/bone-marrow-recipient who underwent two 
consecutive RBV treatments of 4 and 7 months respectively.245 Although at the end of each 
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treatment period, HEV RNA status was negative, viral RNA was detected again shortly after 
stopping therapy. ALT levels normalized rapidly, but γGT remained above normal and 
strongly increased during the second RBV course (figure 5.1 B). To explore the underlying 
causes of non-responsiveness to RBV in both patients, complete HEV genome sequences 
before, during and after treatment were compared. In both patients, a unique G-to-A 
nucleotide substitution was identified resulting in a G1634R mutation in the C-terminal 
region of the HEV polymerase. Comparison of HEV sequences in GenBank revealed that 
K1634 is the predominant amino acid in genotype 1 and 4, whereas in genotype 3 G1634 is 
more common (77%) than R1634 (22%, mostly subgenotypes 3e-f) (table 5.2). 
 
Figure 5.2 RBV treatment failure is associated with a G1634R mutation. Clinical course and 
sequencing results for patients experiencing RBV failure; arrow indicates RBV dose reduction. 
 
Genotype Number of 
sequences 
Sequences with 
G1634 (%) 
Sequences with 
R1634 (%) 
Sequences with 
K1634 (%) 
1 76 0 (0) 2 (3) 73 (96) 
2 1 0 (0) 1 (100) 0 (0) 
3 103 79 (77) 23 (22) 1 (1) 
4 85 1 (1) 6 (7) 78 (92) 
Total 265 80 (30) 32 (12)  152 (57) 
Table 5.2 Prevalence of G, R and K at position 1634 per genotype. HEV sequences from 
genotypes 1 to 4 for which a sequence of the C-terminal RdRp was available were used to 
calculate the prevalence of each amino acid at position 1634. Sequences obtained through 
BLASTP alignment, genotyping based on phylogenetic grouping with known genotype 
sequences (ClustalW2). 
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5.3.2 Polymerase variants G1634R/K enhance HEV replication in a genotype 3 
recombinant replicon assay 
To assess whether the observed G1634R mutation directly confers resistance to RBV, the 
mutation was introduced into the HEV genotype 3 Kernow-C1 p6/luc replicon and resulting 
replicon was tested for sensitivity to RBV, in parallel to the wt construct.159,189 No difference 
in RBV sensitivity was found, with calculated EC50 values of 5.1±3.7 and 5.1±4.1 µM for 
G1634 and 1634R respectively (n = 3, p = 0.99, figure 5.3 A). The 1634R construct however 
consistently yielded a higher luminescence output than its wt counterpart suggesting that 
this mutation may increase the overall viral replication. To explore this possibility, Huh7 and 
HepG2/C3A hepatoma cell lines were transfected with capped p6/luc replicon RNA for wt, 
1634R and 1634K. The 1634R construct resulted in Huh7 cells in a 3.4-fold increase in 
luminescence signal compared to the G1634 wt construct (n = 3, p = 0.04). Also the 1634K 
construct resulted in a 2.7-fold higher signal than wt (p = 0.07) (Figure 5.3 B). In HepG2/C3A 
cells, both mutants resulted in a significantly increased signal: 1.6-fold for 1634R (p = 0.02) 
and 2.1-fold for 1634K (p = 0.02) (Figure 5.3 C). Similar results were obtained when 10:1, 1:1 
or 1:10 mixtures of wt and/or mutant RNA were transfected in these cell lines (Figure 5.3 D-
E). For Huh7, significant differences were found between 10:1 and 1:10 mixtures of G1634 : 
1634R (n = 4, p = 0.006) and G1634 : 1634K (p = 0.04) (figure 5.3 D). Results in HepG2/C3A 
cells were fully in line with this (figure 5.3 E). Because the Gaussia luciferase is translated 
from a subgenomic RNA in this replicon,189 its expression is dependent on viral replication, 
suggesting that the observed increase in luminescence is the result of an increase in viral 
fitness. 
Chapter 5: A mutation in the hepatitis E virus RNA polymerase promotes its replication and 
associates with failure of ribavirin treatment in recipients of organ transplants 
 
78 
 
 
Figure 5.3 G1634R in a HEV genotype 3 replicon. (A) G1634R does not alter the sensitivity to 
RBV (n = 3). (B-C) Luminescence read-out is increased in 1634R/K compared to the wt G1634, 
both in Huh7 (B) and HepG2/C3A (C) cells (n = 3). (D-E) A similar pattern is observed when 
mixtures of G1634 : 1634R (G:R), G1634 : 1634K (G:K) and 1634R : 1634K (R:K) in 10:1, 1:1 
and 1:10 ratios are transfected into Huh7 (D) and HepG2/C3A (E) cells (n = 4). * p < 0.05, ** p 
< 0.01. 
5.3.3 Mutation to 1634R/K increases replication of infectious full-length 
genotype 3 HEV 
The impact of the 1634R/K mutations on the replication and production of viral progeny of 
full-length genotype 3 HEV was studied by transfection of Huh7 and HepG2/C3A cells and 
quantification of viral RNA by RT-qPCR. The 1634R variant replicated to higher titers than the 
wt strain at all time points (days 3-20 post transfection) (figure 5.4 A, control), there is a 
stronger increase in released viral RNA over time compared to the wt strain. A similar, 
although slightly less pronounced difference was observed when the replication of the 
1634K mutant was compared to wt. These observations are in line with the pattern observed 
for the p6/luc replicon in these cells (figure 5.3 B). When treated with RBV at 10 or 25 µM 
(which is in the range of reported RBV serum concentrations)234,235, replication and progeny 
production was found to be partially reduced (figure 5.4 A). Also in the presence of RBV, the 
same pattern in relative replication efficiency was observed for the 3 variants. For RBV at 25 
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µM, the amount of viral RNA decreases initially (loss of input from RNA transfection) before 
increasing again (as a result of viral replication): for 1634R, this increase commences at day 
10 post transfection whereas it is delayed to day 13 for G1634 wt. Intracellularly, viral RNA 
copies per µg total RNA are at least 2-fold higher for 1634R/K compared to G1634, with 
1634R levels slightly higher than those for 1634K (figure 5.4 B). In transfected untreated 
HepG2/C3A cells, a similar pattern was observed, although somewhat less pronounced than 
in Huh7 cells (figure 5.4 C). Treatment of transfected HepG2/C3A cells with RBV at 10 or 25 
µM resulted in a strong inhibition of viral replication so that no differences in replication 
could be observed (figure 5.4 C). Results for intracellular replication in HepG2/C3A are fully 
in line with those for released viral RNA (figure 5.4 D); the fact that the number of HEV RNA 
copies per µg intracellular RNA is higher at 25 µM than at 10 µM is mostly due to the 
decreased amount of total intracellular RNA caused by the (limited) cytotoxicity of RBV. 
 
Figure 5.4 Effect of G1634R/K on full-length genotype 3 HEV replication. (A) Kinetics of 
released viral RNA after transfection in Huh7 cells indicate an increased replication for 
1634R/K strains compared to wt G1634, both in untreated (control) or RBV treated cells (10 
or 25 µM) (n = 3). (B) Intracellular viral RNA from transfected Huh7 cells reveals a similar 
pattern as in released RNA with 1634R/K levels slightly above those of wt G1634 (n = 3). (C) 
Kinetics of released viral RNA after transfection in untreated and RBV-treated HepG2/C3A 
cells (n = 3). (D) Intracellular viral RNA from transfected HepG2/C3A cells (n = 3).  
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5.3.4 1634R outcompetes G1634 in a viral competition assay 
To properly compare the fitness of two viral strains, replication needs to be analyzed in a 
direct competition assay.246 To this end, Huh7 and HepG2/C3A cells were transfected with 
mixtures of G1634 : 1634R capped full-length viral RNA in respectively 10:1, 1:1 or 1:10 
ratios (90, 50 and 10% G respectively) and were cultured further for 20 days. The evolution 
of the fraction of both variants released into the culture medium was monitored by 
multiplex allele-specific RT-qPCR (figure 5.5 A). The proportion of G1634 was experimentally 
confirmed to be 12 ± 1, 45 ± 1 and 88 ± 1 % in the input RNA and decreased to respectively 
2.2 ± 0.4, 17 ± 1 and 61 ± 2 % in Huh7 cells and respectively 2 ± 2, 18 ± 4 and 64 ± 2 % in 
HepG2/C3A cells over the course of a 20-day incubation. This corresponds to relative fitness 
gains (s) of 7 to 9% over 20 days and up to 15% for the first 10 days post transfection. A 
similar pattern was noted in the cell lysates 20 days post transfection as compared to input 
RNA (figure 5.5 B, n = 3, p < 0.001). Taken together, these results provide a strong indication 
that 1634R (and most probably also 1634K) has an increased fitness compared to wt when 
introduced into a genotype 3 background. 
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Figure 5.5 Competition assay for G1634 vs 1634R. (A) Mixtures of G1634 and 1634R full-
length genotype 3 HEV RNA were transfected into Huh7 or HepG2/C3A cells and the fraction 
of wt G1634 in released viral RNA was monitored over time with allele-specific RT-qPCR, 
indicating gradual outcompeting of G1634 by 1634R (n = 3). (B) Comparing input RNA with 
intracellular viral RNA 20 days post transfection shows a similar decrease in the fraction 
G1634 (n = 3). *** p < 0.001. 
5.3.5 K1634 is optimal for genotype 1 HEV replication 
To assess whether the influence of 1634 mutations on viral fitness may also hold for other 
HEV genotypes, an additional recombinant replicon assay system was employed, namely the 
genotype 1 Sar55/S17/luc replicon.243 This strain originally encodes K1634 which was 
mutated to 1634R, 1634G and 1634E. As expected based on our genotype 3 data, 1634G 
yielded a decreased signal compared to wt K1634 (0.7-fold, n = 4, figure 5.6 A). Surprisingly, 
the 1634R mutant also resulted in a decreased replication in the genotype 1 background 
(0.8-fold, n = 3), albeit not statistically significant. The 1634E mutant displayed a significantly 
impaired replication phenotype (0.4-fold reduction compared to wt, n = 4, p = 0.049) as was 
expected, given the fact that this is a negatively charged amino acid, contrary to the 
positively charged R and K residues. However, though obviously suboptimal for viral 
replication, a charge reversion at 1634 still seems to be viable, given that luminescence 
counts remained considerably above the background signal (usually around 1000 RLU). 
 
Figure 5.6 K1634 mutants in a genotype 1 HEV replicon. (A) Replication is decreased in 
1634G/R/E compared to the wt K1634 in Huh7 cells (n = at least 3). (B) Viral replication is 
also impaired for 1634Q and even further for a combination of 1346G+1634Q (GQ) (n = 4). 
The combinations 1498P+1634Q (PQ) and 1346G+1498P+1634Q (GPQ) result in a lethal 
phenotype (n = 3). * p < 0.05. 
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All available HEV sequences feature either G, R or K at position 1634 (table 5.2). Only a single 
exception was found in a genotype 1 strain with Q1634, isolated from an Indian patient with 
fulminant hepatic failure (IND-FHF2-2004, GenBank accession number JF443723).247 To test 
whether this mutation may enhance viral growth and might thus be linked to the observed 
severity of disease, it was introduced into the genotype 1 Sar55/S17/luc replicon. As shown 
in figure 5.6 B, 1634Q resulted in a decreased replication (0.5-fold compared to wt, p = 0.11), 
similar to what was observed for 1634E (figure 5.6 A). Since it may be possible that other 
mutations in the viral RdRp compensate for the reduced fitness of Q1634, we selected 2 
additional mutations unique to the IND-FHF2-2004 strain: C1346G and S1498P were 
introduced either alone or together into the existing 1634Q mutant replicon and their in 
vitro replication capacity was assessed. Introducing 1346G further decreased the already 
impaired replication of the 1634Q mutant (0.2-fold compared to wt K1634, n = 4, p = 0.01), 
whereas 1498P and the triple mutant resulted in a lethal phenotype with no apparent 
replication (n = 3, p = 0.02 for both) (figure 5.6 B). Although other compensatory mutations 
may be present in the RdRp or elsewhere in the HEV genome, these results raise the 
question whether the IND-FHF2-2004 sequence represents a viable virus, or rather a 
defective genome that arose during the (fulminant) course of infection. Moreover, the array 
of replication phenotypes (high: K, intermediate: G/R, low: Q) in genotype 1 corroborates 
the importance of the C-terminal RdRp domain in HEV replication in general. 
5.4 Discussion 
Based on a number of case reports, extended RBV treatment seems to be a viable option for 
the treatment of chronic hepatitis E.148,150,215 However, treatment failure may occur, often 
due to a necessary dose reduction because of anemia (see for instance 216). Here we report 
two particular cases of RBV treatment failure in chronic hepatitis E. Sequencing of viral 
isolates pre and post onset of non-responsiveness indicated that a G1634R mutation was 
associated with loss of RBV efficacy. In vitro testing in a genotype 3 replicon system showed 
that this mutation did not alter overall sensitivity to RBV but rather resulted in increased 
viral replication. In fact, a higher replication fitness of 1634R (and 1634K) was confirmed by 
faster viral growth kinetics and increased viral fitness in competition assays using the 
cognate full-length infectious HEV. These observations were confirmed using a genotype 1 
replicon (native K1634) where 1634R and 1634G both slightly decreased viral replication, 
suggesting K1634 to be the optimal residue at this position for genotype 1. This is in line with 
the observed dominance of K1634 in available genotype 1 sequences (table 5.2). A stronger 
impairment was observed for the oppositely charged 1634E mutant, although still viable. 
Studies into a potential 1634Q mutant and possible compensatory mutations resulted in 
strongly impaired or lethal phenotypes. Overall, these results suggest that the 1634 site 
plays a critical role in HEV replication in at least the two genotypes studied here. 
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This is the first reported putative virulence/fulminance mutation in the HEV genome that has 
been confirmed in in vitro studies. The increased replication capacity of the mutant may 
have resulted in higher intrahepatic and serum HEV titers in the patient, despite RBV 
therapy. Indeed, we observed that the 1634R mutant HEV possesses a replication advantage, 
also in the presence of RBV. Therefore it seems reasonable to assume that the appearance 
of this mutation has contributed to the lethal and seemingly RBV-resistant disease course 
clinically observed. The impact of viral polymerase mutations on the clinical phenotype has 
been firmly established, for instance for the influenza virus where increased polymerase 
activity has been reported to result in high virulence.248,249 Other factors, both patient- and 
virus-related, may have contributed to this particular clinical course reported in the current 
study. 
The G1634 residue is located in the C-terminal region of the HEV RdRp, based on 
computational alignments by Koonin and colleagues.85 A tempting hypothesis would be that 
the G1634R mutation increases the RdRp activity in genotype 3 HEV. It is however unclear 
whether this C-terminus is an essential part of the viral polymerase or perhaps has some 
other function and/or activity for viral replication. Another possibility could be that the C-
terminal region interacts with a cellular host factor. When comparing the results of 1634R 
and K in Huh7 and HepG2/C3A (figures 5.3-4), it seems that there are small differences 
between both cell lines. If the mutation would solely affect the RdRp activity, a highly similar 
pattern would be expected. 
A question of direct clinical importance raised by the cases and data presented is how and 
why this particular G1634R mutation has occurred. Although selection for this particular 
1634 mutation could have been a mere coincidence, an alternative explanation can be found 
directly in the use of RBV. RBV was first identified as mutagenic on in vitro poliovirus 
replication236 and also found to occasionally exert an in vivo mutagenic effect on HCV RNA in 
chronic hepatitis C patients.250,251 RBV seems to preferably induce G-to-A mutations,236 
which is also the type of mutation observed in this particular case (GGG to AGG on the 
nucleotide level). There are currently no data available on in vivo mutagenic effects of RBV 
on HEV replication making this an interesting area to explore. In vitro studies indicated 
depletion of cellular GTP pools as the mechanism of action for RBV against HEV,159 but this 
does not exclude the possibility of (some degree of) in vitro or in vivo mutagenesis by RBV. 
It is also remarkable that G1634 remains the predominant sequence found in clinical and 
animal genotype 3 isolates (table 5.2), despite the increased fitness observed for 1634R. 
Possible explanations include a general evolution of genotype 3 strains towards reduced 
pathogenicity (especially in order to establish persistent infections) or a possible advantage 
of G1634 in other environments, for instance during their zoonotic transmission. 
Nevertheless, the improved in vitro replication of 1634R may represent another step 
forward towards a HEV strain with highly efficient replication kinetics in culture. 
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For future studies, it would be interesting to assess the possible clinical use of sequencing 
position 1634 as a diagnostic and/or prognostic marker. Based on our observations, the 
presence of R1634 or evolution to G1634R in genotype 3 infections may be a red flag that 
warrants a closer follow-up of the patient and possibly more vigorous therapy. Nevertheless, 
cases such as the one presented here highlight the need for more potent and safer HEV 
inhibitors240 and detailed characterization of the modalities of RBV therapy for chronic 
hepatitis E. 
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Chapter 6: mTOR-inhibitors may aggravate chronic 
hepatitis E 
 
This chapter has been published as an editorial: 
Debing Y, Neyts J. 2014. mTOR-inhibitors may aggravate chronic hepatitis E. J Hepatol 
61:720-2. 
  
Chapter 6: mTOR-inhibitors may aggravate chronic hepatitis E 
 
86 
 
6.1 Editorial 
Although HEV is a much understudied pathogen, it is one of the most important causes of 
acute hepatitis worldwide. Based on calculations for genotypes 1 and 2, an annual incidence 
of 20 million HEV infections resulting in about 70 000 deaths has been estimated.114 These 
two genotypes are endemic in developing countries and cause large-scale water-borne out-
breaks,239 such as the very recent outbreak in Nepal (www.promedmail.org; archive number: 
20140509.2461705). A hallmark for such outbreaks is the high morbidity and mortality 
observed in pregnant women, with fatality rates up to 25%. The underlying pathogenesis for 
this particular vulnerability of pregnant woman is only very poorly understood,114,184,239 
although progesterone receptor polymorphisms may play a role.202 Genotypes 3 and 4 are, 
by contrast, zoonotic pathogens that are frequently detected in commercial pig herds, but 
also in wild boar and deer.184,239 The consumption of un- or undercooked pork is, as 
consequence, a major risk factor for contracting hepatitis E. Accordingly, the south of France 
is considered to be a hyperendemic regio because of the popularity of local delicacies, such 
as figatellu, that are prepared with raw pork.115,184 
In general, most HEV infections are asymptomatic and most symptomatic infections resolve 
spontaneously.184,239 Nevertheless, some patients may evolve to fulminant hepatitis, 
explaining the reported overall mortality rates of 0.5–4%.184 Since 2008, it is known that 
hepatitis E can evolve to chronicity in immunocompromised patients.131 Chronic hepatitis E 
has since been observed in HIV patients and leukemia patients undergoing chemotherapy, 
but most cases are organ transplant recipients receiving immunosuppressive treatment.239 
About 30% of chronic infections in the latter group can be resolved by reducing the level of 
immunosuppression.133 Commonly used immunosuppressive drugs in the transplant setting 
are corticosteroids, MMP, calcineurin inhibitors (cyclosporin A and tacrolimus) and the 
mTOR inhibitors such as rapamycin and everolimus. Zhou et al. demonstrate that the latter 
two drugs promote in vitro HEV replication through inhibition of mTOR.1 Thorough studies of 
the involved signaling pathways reveal that mTOR is part of an antiviral signaling pathway 
that inhibits HEV replication. This antiviral activity is mediated through the eIF4E-binding 
protein 1 (4E-BP1) directly downstream of mTOR. 
In another recent study by the same authors, the in vitro effect of other immunosuppressive 
drugs on HEV replication was reported.96 While steroids were shown to have no effect on 
viral replication, the calcineurin-targeting drugs cyclosporin A and tacrolimus resulted in a 
pronounced proviral effect which was shown to be mediated by the inhibition of cyclophilins 
A and B. By contrast MPA (the active component of MMP) was shown to be an inhibitor of in 
vitro HEV replication.159,96 This antiviral effect may be in line with a clinical observation that 
the use of MMP was associated with HEV clearance.83 It should be noted though that this 
observation was based on a small number of patients. 
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These findings raise the question whether the immunosuppressive drug scheme should be 
adapted for patients with chronic hepatitis E. Should calcineurin and mTOR inhibitors be 
avoided and MMP (and possibly steroids) be preferred if a patient in need of 
immunosuppression has been shown to be HEV positive? Should such preferences be 
extended to non-infected patients who are at risk of contracting chronic hepatitis E (such as 
for example pig farmers)? One important caveat is that such recommendations would be 
solely based on in vitro findings that possibly do not take all aspects of hepatitis E 
pathogenesis into account. For instance, the in vitro anti-HEV activity of MPA is mediated by 
an efficient depletion of intracellular GTP pools in cell cultures; an antiviral effect that can be 
easily reversed upon exogenously addition of guanosine.159 It is however questionable 
whether such strong depletion of GTP pools by MMF is at all possible in the human liver.228 
Even if MMF would be able to deplete GTP pools in the liver to levels that may be sufficiently 
low to impact HEV replication, the virus may, in an immunocompromised environment, not 
necessarily be much limited in its replication. MPA also efficiently and completely inhibits 
the in vitro replication of a number of flaviviruses.227 Yet in a murine model for flavivirus 
infection, we did not observe any protective activity of MMF (our unpublished data). 
Similarly, addition of MMF to IFN for the treatment of IFN-non-responsive chronic hepatitis C 
patients proved ineffective in a clinical trial.252 It will thus be important to explore the impact 
of these different immunosuppressive drugs on HEV replication in (a) relevant infection 
model(s) in animals. HEV replication was recently demonstrated in uPA/SCID mice of which 
the diseased liver had been repopulated with human hepatocytes.253 This, and perhaps 
other, yet to be developed models, may be instrumental to demonstrate the differential 
(anti- and proviral) effects of the different immunosuppressive drugs. Retrospective studies 
on cohorts of chronic hepatitis E patients may allow to unveil whether a link exists between 
the clinical outcome and the choice of immunosuppressant(s). The low number of (reported) 
cases of chronic hepatitis E may complicate such exercise; yet given the recent increase in 
diagnosed cases, such studies may become feasible in the future. 
One may put different hypotheses forward to explain the antiviral defense mechanism 
mediated by mTOR and downstream 4E-BP1. The protein 4E-BP1 is known to be a 
translational repressor: by interacting with the essential eukaryotic initiation factor 4E 
(eIF4E), mRNA translation is inhibited.254 mTOR is known to phosphorylate and, thus to 
deactivate 4E-BP1, thereby releasing eIF4E which then initiates mRNA translation (figure 
6.1). More specifically, 4E-BP1 has important regulatory functions in the IFN response.255 
Cells knocked-out for 4E-BP1 are remarkably resistant to viral infection because of a 
decreased threshold for IFN production.256 This phenomenon is mediated by increased 
mRNA translation of IFN regulatory factor 7 (IRF7) which is normally suppressed by 4E-BP1. A 
similar mechanism may apply to the observed increase in HEV replication caused by 
rapamycin and everolimus. Indeed following inhibition of mTOR activity, 4E-BP1 may not be 
phosphorylated and thus remain associated with eIF4E. In this way, translation of IRF7 or 
other factors would be inhibited, which may in turn result in a decreased IFN response and 
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thus overall increased HEV replication. Other factors may of course be involved as well and 
alternative mechanisms may apply. 
 
Figure 6.1 Schematic outline of the mechanism through which mTOR modulates IFN 
production. When mTOR is inhibited by rapamycin or everolimus, 4E-BP1 is no longer 
phosphorylated and eIF4E is not released, leading to a decreased threshold for IFN 
production and possibly increased HEV replication. 
Most transplant patients with chronic hepatitis E that do not clear the virus by reducing 
immunosuppression are treated with an extended course of RBV.150 Although this therapy is 
mostly effective, cases of treatment failure have been reported.216 Moreover, long courses 
of RBV often result in side effects, including anemia. Modulation of the immunosuppressive 
drug scheme could be a very useful strategy to improve response rates to RBV, decrease the 
number of patients in need of RBV treatment and shorten the treatment time altogether. 
Today potent antiviral drugs are available for the treatment of infections with herpesviruses, 
HIV, HBV, HCV and to a lesser extent influenza viruses. Viral polymerase inhibitors (whether 
targeting DNA polymerases, reverse transcriptases or RdRp’s) have been shown to be 
excellent targets for inhibition of viral replication.257 Using a combination of highly potent 
and well-tolerated antivirals, including nucleoside polymerase inhibitors, several studies 
recently reported a sustained virological response cure in >95% of patients chronically 
infected with the hepatitis C virus.258 This latter virus is, akin to HEV, a positive-sense single-
stranded RNA virus and encodes several proteins (including a RdRp) that may be good 
targets for pharmacological inhibition of viral replication.240 In fact, it has been shown that 
some HCV nucleoside polymerase inhibitors (in particular the 2’-C-methyl series) inhibit the 
replication of yet other positive-sense single-stranded RNA viruses including, but not limited 
to flaviviruses, enteroviruses and noroviruses.259 It remains to be studied whether (some of 
the) HCV nucleoside polymerase inhibitors that have, or will reach the market, also inhibit 
HEV replication. In such a case, they may be used (even off-label) either alone, or in 
combination with RBV, for the control of HEV infections. If such combination treatment 
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would be sufficiently potent, there may no longer be a need to reduce immunosuppression 
to control chronic HEV infection in immunodeficient patients. 
In conclusion, the work by Zhou and colleagues highlights the potential importance of 
choosing the most appropriate immunosuppressant for use in patients with chronic hepatitis 
E. Confirmation of the observed in vitro effects in a suitable animal model for hepatitis E is 
awaited. Retrospective analyses (and if possible prospective studies) of immunosuppressive 
regimens in chronic hepatitis E patients will also help to understand the potential effect of 
immunosuppressive drugs on HEV replication in the infected patient. 
  
 
90 
 
 
  
 
91 
 
 
Chapter 7: Complete genome sequence of a rat hepatitis E 
virus strain isolated in the United States 
 
This chapter has been published in the following paper: 
Debing Y, Emerson SU, Purcell RH, Neyts J, Dallmeier K. 2014. Complete genome sequence 
of a rat hepatitis E virus strain isolated in the United States. Genome Announc 2:e01096-14. 
  
Chapter 7: Complete genome sequence of a rat hepatitis E virus strain isolated in the United States 
 
92 
 
HEV is a common cause of acute hepatitis in humans. Related viruses have been isolated 
from multiple animal species, including rats, but their impact on human health is unclear. 
We present the first full-length genome sequence of a rat HEV strain isolated in the US (LA-
B350). 
7.1 Genome announcement 
HEV is a positive sense, single-stranded RNA virus and is a major cause of acute hepatitis 
worldwide.240 Severe infections with high mortality may occur in pregnant women and 
chronic infections have been described in immunocompromised patients.239 HEV belongs to 
the Hepeviridae family that also comprises several related viruses isolated from different 
animals including rats, ferrets, bats, rabbits, chickens, and teleost fish.260 The 
epidemiological aspects and public health impact of these animal viruses are unclear to date, 
also for rat HEV. At present, 10 full-length rat HEV genomes are available, including 
sequences isolated from Germany, Indonesia and Vietnam.261 Rat HEV has also been 
detected in other regions such as the United States, Denmark and China,262–265 but no full-
length sequences have been determined for these strains yet. 
Here we present the first full-length rat HEV sequence isolated in the United States. The 
virus was originally isolated from rats trapped in urban Los Angeles, passaged twice in 
Sprague-Dawley rats and once in an athymic nude hooded rat (B350), as reported.262 Total 
RNA was extracted from 100 µL of a 10% liver homogenate from rat B350 with the Qiagen 
RNeasy kit and viral RNA was amplified using the One-Step RT-PCR kit (Qiagen) and KAPA 
HiFi HotStart ReadyMix PCR kit subsequently. Primers were designed using relatively 
conserved regions in an alignment of known rat HEV sequences and strain-specific 
sequences as they became available. Fragments were gel-purified, cloned into the pJet1.2 
vector using the CloneJET PCR cloning kit (Thermo Fisher Scientific) and sequenced with the 
BigDye Terminator v3.1 cycle sequencing kit (Life Technologies). Sequences were assembled 
and manually edited to obtain a complete consensus sequence.266 
The genome of this particular rat HEV strain, designated LA-B350, is 6942 nt in length 
(excluding the poly(A)-tail) and encodes the expected ORF1 (1634 aa), ORF2 (644 aa), ORF3 
(102 aa) and also the ORF4 (183 aa) that seems to be conserved in rat and ferret HEV.261 The 
highest nucleotide homology was found with the Indonesian ratESOLO-006SF strain (87.8%) 
and the German rat/Mu09/0434/DEU/2010 strain (87.6%) which have been provisionally 
classified into genetic group 1. This lineage also includes all other known German strains.261 
Phylogenetic analyses of the full-length LA-B350 confirmed its classification into the first 
genetic group (designated G1, figure 7.1). Sequence variation observed in the cloned partial 
cDNAs was on average 2 × 10-3, and may thus be slightly higher than expected for errors 
introduced by reverse transcription (range of 10-4 - 10-5)267 and PCR (approximately 10-4) 
(http://www.qiagen.com/media/ebooks/Maximising_PCR_and_RT_PCR/index.htm) 
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suggesting that LA-B350 may exist as a diverse viral quasispecies, as was described for 
human HEV as well.268 
 
Figure 7.1 Phylogenetic classification of all known full-length rat HEV sequences, using ferret 
HEV as an outgroup. Tree was generated using ClustalW2 with the UPGMA clustering 
method. Rat HEV has been provisionally classified into 3 genetic groups, designated G1, G2 
and G3.261 
In conclusion, the availability of the first US rat HEV genome may help in further elucidating 
rat HEV epidemiology and its possible impact on human health. 
7.2 Nucleotide sequence accession number 
The complete genome of rat HEV strain LA-B350 can be accessed under the GenBank 
accession no. KM516906. 
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Chapter 8: General discussion 
 
HAV and HEV are the most common causes of acute viral hepatitis worldwide, but both 
viruses have remained largely understudied. In addition, there is no curative treatment for 
hepatitis A and current therapies for (chronic) hepatitis E are not ideal since they are 
associated with serious side effects and may result in treatment failure. 
HAV is classified in the Hepatovirus genus of the Picornaviridae family.161 Infections are often 
asymptomatic, but may lead to a typical clinical picture of acute hepatitis with jaundice, 
fever and general malaise. Asymptomatic hepatitis A is very common in children, while the 
number and severity of symptomatic infections increases with age. Although most HAV 
infections resolve spontaneously, some patients experience relapsing infection or fulminant 
hepatitis with increased mortality, particularly the elderly. On the other hand, 
superinfections with HAV in chronic hepatitis B or C patients may lead to increased 
morbidity and mortality,7,8 although this notion has been challenged.10 HAV is transmitted 
feco-orally and therefore epidemics most often occur in regions with poor sanitation and 
hygiene. In addition, outbreaks are still rather frequently reported in developed 
countries,13,162 despite the availability of effective vaccines. The current treatment is merely 
supportive; consequently, a safe and potent anti-HAV drug would be very useful for severe 
infections, to contain epidemics, but also to decrease the long period of illness. 
In order to identify and develop such inhibitors of HAV replication, a convenient screening 
system is required that is amenable to high-throughput screening. We employed the CPE-
inducing HM175/18f HAV strain on FRhK-4 cells to develop a CPE-reduction assay with an 
easy MTS/PMS-based read-out and confirmed assay quality with a Z’ value of 0.63. For 
further confirmation and characterization, virus yield assays were developed with the 
HM175/18f and the PA21 strain (genotypes IB and IIIA respectively) in which the amount of 
virus produced in the presence of a potential antiviral compound is quantified by RT-qPCR. 
All 3 assays were validated with the known HAV inhibitors IFNα and amantadine HCl. IFNα 
resulted in a strong antiviral activity with some (minor) variability in the particular sensitivity 
of the assays while the activity of amantadine HCl appeared to be strain-dependent and 
overall rather limited. Next, three known enterovirus inhibitors were evaluated for their 
activity against HAV since this had not yet been evaluated. Pleconaril is a capsid binder and 
in thus blocks virus receptor binding. Although somewhat unexpected, we observed 
moderate anti-HAV activity in all 3 assays for pleconaril. HAV does not appear to have a 
distinct canyon in its particle structure, contrary to the enteroviruses. Therefore, it would be 
interesting to study the mechanism of action of pleconaril on HAV. Does it bind to the viral 
particle and prevent entry as for enteroviruses, or is a different antiviral mechanism 
involved? Next, rupintrivir was assessed which is an inhibitor of the enteroviral 3C protease. 
Rupintrivir’s antiviral effect proved to be strain-dependent with no activity against the 
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HM175/18f, but a clear inhibitory effect on PA21 replication. Finally, enviroxime was tested 
which is an inhibitor of the host factor PI4KIIIβ and in this way inhibits enterovirus 
replication. No inhibition of HAV was observed however, suggesting that HAV replication 
does not depend on the enzymatic activity of PI4KIIIβ. In conclusion, the antiviral assays 
described here for HAV are a first step towards the identification and development of potent 
and selective inhibitors of HAV replication. 
Like HAV, HEV is a positive-sense single-stranded RNA virus that is transmitted feco-orally 
and is an important cause of acute viral hepatitis.240 HEV is classified into the Hepevirus 
genus in the Hepeviridae family. At least four major genotypes infecting humans have been 
described. Genotypes 1 and 2 are mainly transmitted through contaminated water and 
exclusively infect humans. On the other hand, genotypes 3 and 4 are zoonotic agents that 
are often identified in commercial pig herds, but also in wild boars and deer. Infection with 
the latter genotypes seems to be caused by consumption of undercooked pig meat. HEV 
infections are often asymptomatic or cause a mild hepatitis. Nevertheless, fulminant 
hepatitis is possible, contributing to the general mortality rates reported between 0.5 and 
4%. Two notable exceptions to this have been observed: pregnant women infected with 
genotype 1 HEV may experience severe disease with fatality rates up to 25% and a 
substantial risk of stillbirth. Second, immunocompromised patients such as transplant 
recipients or AIDS patients seem to be susceptible to chronic infections with genotype 3 
HEV. Such chronic infections are currently treated with a reduction of immunosuppresion if 
possible and/or RBV or IFNα monotherapy, although none of these therapeutic options is 
ideal and they may even result in treatment failure. 
Since HEV replication in culture has been a difficult undertaking until recently, we aimed to 
develop a surrogate model based on the HEV-related fish virus CTV. This virus has a similar 
genome organization as HEV and some degree of sequence conservation.106 In addition, 
many of the enzymatic motives of the non-structural proteins are highly conserved. CTV was 
originally isolated from spawning adult trout and it generally only detected during spawning. 
It does not appear to have pathogenic effects in vivo, however, it replicates efficiently in cell 
culture, generating a diffuse type of CPE in CHSE-214 cells.106 Since this CPE was not 
sufficiently extensive to be used as a read-out for a robust antiviral assay, a RT-qPCR-based 
virus yield assay was developed in which CHSE-214 monolayers are infected with CTV and 
incubated at 15°C for 14 days. Afterwards, viral RNA was extracted from culture medium and 
quantified by RT-qPCR. This assay was employed to confirm the observed clinical efficacy of 
RBV and IFN. Indeed, both RBV and rtIFN2 effectively inhibited HEV replication. The broad-
spectrum RNA virus inhibitors 2’CMC and T705 only yielded very moderate to no antiviral 
activity. Next, we explored if sex steroid hormones can influence in vitro CTV replication: 
high concentrations of progesterone were found to inhibit CTV while its replication is 
stimulated at low concentrations of testosterone and estradiol. This hormone-dependence 
of virus replication may provide a possible explanation for the specific shedding pattern of 
CTV during spawning. In addition, it may be useful to investigate if genotype 1 HEV 
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replication is similarly influenced by sex steroids, as this may provide a possible explanation 
for the severe clinical course observed in some pregnant women. From a virology point of 
view, it would also be interesting to look more closely into the replication cycle of CTV and to 
understand its epidemiology and potential impact on fish populations. 
Recently, the genotype 3 HEV strain Kernow-C1 p6 was described that displayed relatively 
good growth in cell culture.189 In addition, a subgenomic replicon was described in which the 
capsid-encoding ORF2 was replaced with a Gaussia luciferase, allowing for a fast and 
convenient read-out. We employed this strain and replicon to develop two antiviral assays. 
First, the p6/luc replicon was employed in a 3-day luminescence-based replicon assay in 
Huh7 hepatoma cells. RBV and IFNα were tested in this system and both proved to be 
effective inhibitors of HEV replication. When both drugs were combined, a slight synergistic 
effect was observed, suggesting that combination therapy may be a useful treatment 
strategy for chronic hepatitis E. Second, a virus yield assay was developed with the infectious 
Kernow-C1 p6 virus: cultures of hepatoma cell lines were infected with virus and 
consequently incubated for 20 days with regular medium changes to allow for virus 
replication. Similarly to the replicon results, RBV and IFNα reduced the amount of HEV 
produced and a clear dose-dependency was observed for RBV. Next, the replicon assay was 
employed to elucidate the mechanism of action of RBV. Since inhibition of IMPDH with 
consequent depletion of cellular GTP pools has been suggested as a mechanism for RBV, we 
evaluated other IMPDH inhibitors (MPA and EICAR) and found that both effectively inhibited 
in vitro HEV replication. When guanosine was added to the culture to replenish GTP pools, 
the antiviral effect of RBV and the other IMPDH inhibitors was reversed. Finally, a strong 
correlation was observed between the EC50’s for the antiviral effect and the IC50’s for GTP 
depletion, confirming that the depletion of cellular GTP pools is the predominant mechanism 
of action of RBV against HEV replication in vitro. It remains to be elucidated whether such a 
mechanism also applies in vivo, as it may be difficult to deplete the GTP pools of the entire 
liver. Many other mechanisms have been suggested for RBV, such as mutagenesis and direct 
inhibition of viral enzymes, which may also apply for HEV. A good starting point may be to 
quantify the amount of GTP in the rodent liver with and without RBV treatment. 
Nevertheless, we provided compelling evidence that GTP depletion is central to the 
mechanism of RBV in vitro. 
Despite the observed antiviral activity of RBV and several publications describing its efficacy 
in treating chronic hepatitis E, some cases of treatment failure have been observed (e.g. 216). 
In collaboration with the University Hospital in Hannover, we aimed to investigate such 
treatment failure. In a cohort of 15 solid-organ transplant patients who were treated with 
RBV, two cases of treatment failure were observed. The first patient never succeeded in 
clearing the virus; after an initial decrease in viral RNA, the titers re-increased to baseline. 
This infection proved to be lethal. A second patient was treated twice with RBV and became 
HEV RNA negative during each treatment, but viral RNA was detected again shortly after 
stopping RBV treatment. Since the observed clinical pattern (especially in the first patient) 
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was reminiscent of the development of resistance to an antiviral drug, viral genomes were 
sequenced before, during and after RBV treatment. A G-to-A mutation was found in the viral 
RdRp gene corresponding to a glycine-to-arginine mutation at position 1634 in both patients. 
When this particular mutation was introduced into the Kernow-C1 p6/luc replicon, no 
resistance to RBV was observed, but an increased luminescence signal was observed. 
Subsequent viral growth kinetics and competition experiments confirmed an increased 
fitness of the 1634R mutant over the original G1634 variant, even in the presence of RBV. 
This increased replication capacity may provide an explanation for the observed clinical 
patterns. It is still unclear however what the underlying mechanism is for this fitness 
increase. One possible hypothesis is that this mutation increases the processivity of the viral 
polymerase, thus resulting in increased virulence. An appropriate way to investigate this 
would be through enzymatic assays with the purified HEV RdRp; however, proper expression 
and purification of this protein appears to be problematic to date. Such enzymatic assays 
would also be useful to further our understanding of the mechanism of action of ribavirin. 
More research is required to confirm the role of G1634R/K mutations in chronic hepatitis E 
and RBV treatment failure. Possibly the sequencing of this particular position during RBV 
treatment may have some prognostic value: mutation of G to R may be a red flag, 
warranting closer follow-up and more vigorous therapy if possible. The observed failure of 
RBV treatment also highlights the need for more potent and less toxic treatment options for 
(chronic) hepatitis E. 
For transplant patients with chronic hepatitis E, another treatment option is the reduction of 
immunosuppresion (if possible), which seems to result in viral clearance in about 30% of the 
cases.133 In addition, the particular choice of immunosuppressant may also influence the 
disease course of (chronic) hepatitis E; for instance, the use of MMP was associated with 
HEV clearance in a small cohort of patients83 and another study found a strong proviral 
effect for cyclosporin A and tacrolimus in vitro.96 In a recent study,1 it was reported that 
mTOR inhibitors increase HEV replication in vitro. mTOR appears to be part of an antiviral 
signaling pathway through its downstream effector 4E-BP1. In an editorial, we provide 
background and discuss the potential implications of these results. It would be highly 
relevant to confirm these in vitro findings in an experimental animal model, with 
retrospective analyses of chronic hepatitis E patients under immunosuppresion and if 
possible in a prospective clinical trial. 
To further advance the study of HEV and its potential inhibition by antiviral drugs, a small 
animal model would be highly appreciated. Current model include pigs and non-human 
primates, but these are not convenient, very expensive and may be questionable from an 
ethics point of view. Experimental infections of laboratory rodents with human HEV have not 
been very successful. However, a rat variant of HEV was recently isolated and is infectious in 
laboratory rats, especially athymic nude rats,262 although the observed pathology is limited. 
We aim to further optimize this model. As a first step in this endeavor, we sequenced the 
entire genome of a US strain of ratHEV, designated LA-B350. This information may 
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contribute to the current understanding of ratHEV epidemiology and the amplified 
fragments will be used to construct a full-length cDNA clone that can potentially be used to 
generate infectious RNA. This would for instance allow for mutation studies and the 
generation of a subgenomic replicon. Another possibility could be to construct viable 
chimeras of human and rat HEV to further increase the relevance of rat HEV as a model 
system. 
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Abstract of the research 
Hepatitis A virus (HAV) and hepatitis E virus (HEV) are the most common causes of acute 
hepatitis worldwide, but current therapies are either not available (HAV) or remain 
insufficient (HEV). To address these needs, we developed novel antiviral assays for both 
viruses. For HAV, these assays were employed to assess the activity of known enterovirus 
inhibitors against HAV; whereas for HEV, the observed clinical efficacy of ribavirin and 
interferon alpha were confirmed in vitro. The mechanism of action for ribavirin against HEV 
replication was studied more in depth and was found to depend on the depletion of 
intracellular GTP pools. Despite the in vitro and in vivo activity of ribavirin, some cases of 
treatment failure have been reported. Two such cases were investigated and were 
associated with a G1634R mutation in the HEV RNA-dependent RNA polymerase. 
Characterization of this mutation indicated that it did not confer in vitro ribavirin resistance, 
but that it increased HEV replication and thus viral fitness, which may explain the observed 
clinical courses. Another possible strategy to treat transplant patients with chronic hepatitis 
E is to decrease the immunosuppressant dosage if possible. Recent evidence suggests that 
the choice of immunosuppressant may also be an important factor in development of 
chronicity. We discuss these findings in an editorial. Finally, the complete genomic sequence 
of the first rat HEV strain isolated in the United States was determined as a first step in 
developing a convenient rodent model for HEV. 
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